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1. Summary 
Cell-based assays can be adopted as in vitro method to evaluate the 
bioavailability and functionality of different nutraceutical and bioactive 
compounds, particularly in view of the need to use alternatives to animal 
studies. The interest in these bioactive compounds in animal sciences is not 
only related to medical research. It also represents an enormous benefit for 
health food companies and the animal produce sector in general. 
The general aim of my PhD study was to evaluate nutraceutical effects at a 
cellular level in response to different stress challenges.  
In the first section of my thesis, the protective role of α-tocopherol in 
counteracting the cytotoxicity and DNA damage induced by Ochratoxin A 
(OTA) in primary porcine fibroblast cell cultures (ear and embryo), was 
determined by using the MTT assay, LDH release, DNA fragmentation, and 
TUNEL stain. 
The aim of the second section was to evaluate the protective role of bovine 
Lactoferrin (bLf), added to the culture medium, against lipopolysaccharide 
(LPS) cytotoxicity using the established bovine mammary epithelial cell line 
BME-UV1 as an in vitro model of the bovine mammary epithelium. In 
addition, we assessed whether BME-UV1 cells were able to express 
endogenous bLf after in vitro exposure to LPS. 
A further objective of my thesis work was to use cell-based bioassays to 
investigate the plasmin-plasminogen system. This system plays a key role in 
cellular responses, and is involved both in physiological and in pathological 
conditions in the mammary gland. The aim of the third section was to 
determine the effect of growth factors (IGF-1 and EGF) and three hormones 
(insulin, dexamethasone, and prolactin) on the expression of plasminogen 
activator (PA)-related genes (u-PA, u-PAR, PAI-1, PAI-2) and BME-UV1 cell 
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proliferation. In addition we investigated the effects of E. coli LPS on cell 
viability, the modulation of cell-associated u-PA activity and the regulation of 
u-PA and u-PAR RNA expression in BME-UV1 cells. 
Below are more details on what each section covers: 
The first section reports how the role of α-tocopherol in counteracting OTA 
toxicity was evaluated in various experimental conditions using primary 
porcine fibroblasts. Cells showed a dose-, time- and origin-dependent (ear vs. 
embryo) sensitivity to ochratoxin A. Pre-incubation for 3 h with 1 nM α-
tocopherol significantly (P < 0.01) reduced OTA cytotoxicity, lactate 
dehydrogenase release and DNA damage in both fibroblast cultures. These 
findings indicate that α-tocopherol administration may counteract short-term 
OTA toxicity, thus supporting its defensive role at a cell membrane level. 
The second section describes how BME-UV1 was used as an in vitro model to 
evaluate the protective role of exogenous bovine Lf (bLf) against the cytotoxic 
damage induced by bacterial lipopolysaccharides (LPS). Exogenous bLf 
showed a protective effect against endotoxin cytotoxicity, which could be 
mediated by the LPS-neutralizing capability of bLf. In addition, in BME-UV1 
cells the response to LPS exposure did not involve endogenous bLf mRNA 
expression, suggesting that this cell line lacks functional LPS-responsive 
elements. 
The third section details how cell proliferation was measured using the MTT 
assay and direct cell enumeration on BME-UV1 treated with physiological 
stimuli. Results showed that both IGF-1 and EGF increased cell proliferation. 
Neither of the growth factors had any effect on the expression of PAI-1 and 
PAI-2. In line with changes in gene expression, EGF and IGF-1 upregulated 
total cell-associated, membrane-bound and secreted u-PA activity. 
Dexamethasone alone and when combined with insulin or prolactin 
upregulated the gene expression of both PAI- and PAI-2, but not that of u-
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PA and u-PAR without affecting cell proliferation. Total decreased cell-
associated, membrane-bound and secreted u-PA activity was detected in cells 
cultured in the presence of dexamethasone when combined with insulin or 
prolactin. However no such effect was observed in the presence of 
dexamethasone alone. This thus suggests that when dexamethasone acts 
synergistically with prolactin or insulin it inhibits the activation of the plasmin-
plasminogen system, but this inhibition is not correlated with any changes in 
cell proliferation. In addition, the plasmin-plasminogen system was examined, 
using the BME-UV1 cell model, in order to evaluate the effects of Escherichia 
coli LPS on cell viability, the modulation of cell-associated u-PA activity, and 
the regulation of u-PA and u-PA receptor (u-PAR) RNA expression. LPS did 
not affect cell viability, but led to an increase in u-PA activity, with the 
maximum response after 6 h of incubation. In addition, u-PA and u-PAR 
mRNA expression were both up-regulated in BME-UV1 cells after 3 h of 
incubation with LPS. These data indicated that E. coli LPS increased u-PA 
activity and RNA expression of u-PA and u-PAR in BME-UV1 cells, thus 
strengthening the role of the PA system during pathological processes.  
In conclusion, the application of appropriate in vitro models represents a 
fundamental requirement for the study of cellular responses to different 
stimuli as in the case covered in my thesis regarding nutraceutical compounds.  
Cell-based assays are a valuable tool for assessing fundamental regulatory 
mechanisms at a cellular level, such as the plasmin-plasminogen system. Cell-
based assays allow both the functionality of nutraceutical and cellular response 
mechanisms to be evaluated reducing use animal models in the preliminary 
study phase. Obviously, data obtained in cell culture models must be 
interpreted carefully, since this system represents a simplification of the 
intricacies of the numerous reactions and interactions that occur in vivo. 
10 
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2. Introduction 
Over the past few years, food and feed sciences have evolved as a result of 
different factors, such as improved safety, changes in the European Union 
agriculture policy, the need to recover consumer confidence and the 
functional aspects of foods, taking into account the changes in the alimentary 
habits of the population. It is well known that food can have biological 
activities that are beyond classical nutritional values. This aspect has gained 
increasing attention in the food industry but also in animal nutrition, and so-
called nutraceuticals are offered both for food and for feed applications. 
Nutraceutical is defined as “a food or part of a food that provides medical or 
health benefits, including the prevention and/or treatment of a disease”. This 
term was coined by DeFelice, in 1989, from “nutrition” and “pharmaceutical” 
(DeFelice, 1995). 
Some years later, the U.S. Institute of Medicine’s Food and Nutrition Board 
defined functional foods as “any food or food ingredient that may provide a 
health benefit beyond the traditional nutrients it contains” (Rodriguez et al., 
2006). 
Nutraceutical differs slightly from functional foods; in fact it refers equally to 
nutraceuticals and functional foods, however some authors (Gulati and 
Ottaway, 2006) differentiate the former from the latter on the basis of its 
formulation.  
Kalra (2003) proposed redefining nutraceutical and functional foods: when 
functional food aids in the prevention and/or treatment of diseases and/or 
disorders other than anemia, it is called a nutraceutical”. The term 
nutraceutical is used to describe substances that range from isolated nutrients 
to processed products. More broadly, nutraceutical refers to all those 
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substances that have positive physiology effects on the human/animal body 
(Gulati and Ottaway, 2006). 
The interest in nutraceutical products has increased over the last decade in 
Europe and reflects the fact that epidemiological surveys, animal research, 
clinical trials and research in nutritional biochemistry indicate that a specific 
diet or dietary supplements are associated with lower risks for a wide range of 
diseases such as cancer, osteoporosis and heart disease. 
From a regulatory point of view, the European Union defines a nutraceutical 
on the basis of its accepted effects on the body: if the substance only 
maintains healthy tissues and organs, it can be considered a food ingredient. 
On the other hand, if it has been proved to modify the effects on the body’s 
physiological processes, then it may be considered as a medicinal substance 
(Fig.1). 
 
Fig. 1: Where nutraceutical stand between food and drug; (modified by Gulati and Ottaway, 2006) 
 
If a vitamin is fed at levels close to the daily requirement (Recommended 
Daily Allowance), it is considered as a food ingredient because it maintains the 
function of healthy organs and tissues. However, if the same vitamin can be 
demonstrated to modify, restore or correct the functions, it, or the product 
containing it, may be considered as medicinal (Gulati and Ottaway, 2006). 
Drug Food Nutraceutical 
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If food and feed are brought onto the market with “nutritional and health 
claims”, these claims must be objective, scientifically supported, and verifiable 
by the competent authorities (Regulation (EC) No 1924/2006 of the 
European Parliament and of the Council; Regulation (EC) 767/2009 of the 
European Parliament and the Council) (Cheli and Baldi, 2011). 
The use of nutraceuticals in human nutrition, as described above, has been the 
focus of many studies and economic interests. Nutraceuticals have also taken 
up a key role in animal dietary studies. Since 2000 following the publication of 
the European Commission’s White Paper, the relationship between health and 
nutrition in European animal production has become increasingly recognized. 
This White Paper stipulated that animal feeds must be subject to the same 
conditions as food for human consumption, and that animal health and 
welfare should be considered in animal production (Baldi, 2005a). 
 
2.1 Bioactive compounds in food 
Many nutraceuticals bioactive compounds show strong antioxidant activity. 
Packer et al. (2004) highlighted the crucial role that antioxidants play in 
preventing oxidative stress and maintaining the physiological redox status of 
cellular constituents: “Antioxidants may quench free radicals, change their 
redox state, be targeted for destruction, regulate oxidative processes involved 
in signal transduction, affect gene expression and pathways of cell 
proliferation, differentiation and death”. This is achieved at various subcellular 
and molecular levels including antioxidants that interact with the redox 
antioxidant network, such as ascorbic acid (vitamin C) and α-tocopherol 
(vitamin E) (Mandel et al., 2005).  
Vitamin E is one of the most important components of cellular antioxidant 
systems. In nature it is present under eight different forms, four tocopherols 
(α-, β-, γ-, δ) and four tocotrienols (α-, β-, γ-, δ), of which α-tocopherol is the 
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most bioactive. As an antioxidant, α-tocopherol can prevent free-radical 
mediated tissue damage, and thus can prevent or delay the development of 
degenerative and inflammatory diseases, thus it has been extensively 
investigated in many species, including humans. According to several surveys, 
vitamin E supplementation helps to enhance animal health and production 
and, when dietary selenium is adequate, it significantly reduces the incidence 
of intramammary infections (IMI) and clinical mastitis (Moyo et al., 2005). 
Vitamin E also seems to be crucially involved in the immune system so that 
supplementation with supra-nutritional levels, at least in some instances, 
results in improved immune responses (Baldi, 2005a). Vitamin E 
supplementation is a common practice in animal nutrition, and increasing the 
feed content of synthetic or natural vitamins is currently considered the best 
way to maintain adequate plasma levels for animal health. 
An important functional food containing a large numbers of bioactive 
components is milk. Milk is a polyphasic secretion of the mammalian gland, 
and is an excellent source of well-balanced nutrients. Its benefits are mainly 
due to its peptides and proteins, which range from facilitating the digestive 
system to the growth and development of specific organs. Some of the 
biological activities of milk protein components are released only upon 
proteolytic action during the digestion of milk in the gastrointestinal tract and 
also during fermentation and food processing (Singh and Sachan, 2011). Milk 
contains many bioactive components such as: vitamin D and vitamin K which 
promote strong bones; vitamin B12 and riboflavin, which are necessary for 
cardiovascular health and energy production; and vitamin A, which is essential 
for the immune function (Singh and Sachan, 2011). In addition, milk 
produced by grass-fed cows contains Conjugated Linoleic Acid (CLA), which 
can play a role in the prevention of some types of cancer such as breast cancer 
and help to prevent atherosclerosis (Midau et al., 2010). 
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 Concentration 
(g/l) 
 
Protein Cow Human Function 
Total Caseins 26.0 2.7 Ion carrier (Ca, PO4, Fe, Zn, Cu) precursors of bioactive peptides 
α-Casein 13.0   
β-Casein 9.3   
κ-Casein 3.3   
Total whey protein 6.3 67.3  
β-Lactoglobulin 3.2  Retinol carrier, binding fatty acids, possible antioxidant 
α-Lactoalbumin 1.2 1.9 Lactose-synthesis in mammary gland, Ca carrier, immunomodulation, 
anticarcinogenic 
Immunoglobulins (A, M 
and G) 
0.7 1.3 Immune protection 
Serum albumin 0.4 0.4  
Lactoferrin 0.1 1.5 Antimicrobial, antioxidative, immunomodulation, iron absorption, 
anticarcinogenic 
Lacoperoxidasetoferrin 0.03  Antimicrobial 
Lysozyme 0.0004 0.1 Antimicrobial, synergistic effec with immunoglobulins and lactoferrin 
Miscellaneous 0.8 1.1  
Proteose-peptone 1.2  Not characterized 
Glycomacropeptide 1.2   Antiviral, bifidogenic 
 
Table. 1: Concentration and biological functions of major milk proteins (Séverin and Wenshui, 2005) 
 
The protein component of milk consists of caseins and whey proteins; in 
bovine milk, caseins comprise about 80 per cent of the total protein content 
and are divided into α-, β- and κ-caseins. Whey proteins consist of β-
lactoglobulin, α-lactoalbumin, immunoglobulins (IgGs), glycomacropeptides, 
bovine serum albumin and minor proteins such as lactoperoxidase, lysozyme 
and lactoferrin (Table.1) (Singh and Sachan, 2011). 
Lactoferrin is a non-haem iron-binding glycoprotein with a molecular weight 
of about 80 kDa, synthesized by glandular epithelial cells. It is found in many 
biological secretions, such as colostrum and milk (Legrand et al., 2008), and is 
stored in the secondary granules of neutrophils (Masson et al, 1966). 
Several physiological roles have been attributed to Lf, including antibacterial, 
antiviral and anticancer activities, the regulation of iron homeostasis, an anti-
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inflammatory role, antioxidant properties, and the modulation of immune 
responses (Ward et al., 2005; Legrand et al., 2008).  
 
Fig. 2: Multifunctional properties of Lf ( Rogan et al 2006). 
The polyfunctionality of Lf is related to its ability to interact with several 
targets (Fig. 2). The function of the iron-chelating activity of the protein is to 
sequester the free element, thus controlling the growth of pathogenic bacteria, 
and limiting the production of reactive oxygen species that can damage 
cellular components (Legrand et al., 2006; Paesano et al., 2009). In addition, a 
growing number of studies have revealed that some of the physiological 
effects of Lf are mediated by the interaction with cellular structures, such as 
lipopolysaccharides (Elass-Rochard et al., 1995), proteoglycans (Legrand et al., 
1997) and cell-type specific receptors (Suzuki et al., 2005). 
Lf is an innate factor of the mammalian immune system and displays a broad-
spectrum antimicrobial activity against both Gram-negative bacteria, such as 
E. coli and Klebsiella sp., and Gram-positive bacteria, including Staphylococcus 
aureus and Streptococcus uberis (Valenti and Antonini, 2005; Rainard and Riollet, 
2006; Jenssen and Hancock, 2009). 
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2.2 In vitro models for the study of bioactive components in 
food/feed 
2.2.1 General introduction 
In order to use nutraceuticals in both human and animal nutrition, it is 
important to develop protocols and models to evaluate the bioaccessibility, 
bioavailability and functionality of the bioactive components. The evolution 
of food analysis over the past few years has led to improvements in chemical 
analysis and instrumental tools with signiﬁcant enhancements in analytical 
accuracy, precision, detection limits, and sample throughput (Mc Gorrin, 
2009). The transition from a chemical analysis approach to cell-based 
bioassays supports the new need for food/feed analysis in terms of bioactivity 
and functional properties. The need for reliable in vitro cellular models as 
alternatives to animal studies has became an important issue and is considered 
in European legislation (http://www.euractiv.com/en/science/eu-wants-
fewer-animals-used-research-news-497607).  
The interest of the food and pharmaceutical industry in cell-based bioassays 
focuses above all on toxicological and bioavailability tests of newly-developed 
food ingredients and drugs, which are key to bringing products to the market. 
In the food/feed industry, research regarding the safety and efficacy of 
additives and new functional food and feed could take benefit from the 
development and validation of speciﬁc cell-based functional bioassays. 
Obviously the use of cell cultures has both advantages and disadvantages. 
Advantages: 
 Control of chemical, physical and physiological conditions 
 Characterization and homogeneity of the samples 
 Low price and speed of response 
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 Possible reduction of animal testing. 
Disadvantages: 
 Depending on the model selected, loss of architecture and three-
dimensional tissue-specific interactions between cells 
 Difficulty to maintain cell differentiation 
 Loss of control systems that depend on the endocrine and nervous 
systems  
 Instability and duration 
 Need for experience and organization 
 
2.2.2 Types of cell cultures 
A cell culture is a generic term used to indicate the process by which cells, 
arising from the breakdown of tissues or isolated from biological fluids such 
as blood, are grown and maintained under controlled conditions. 
In vitro systems have been designed to simulate what occurs in vivo so as to 
preserve both the characteristics of the original tissue and the cell-cell 
interactions (Zucco et al., 2004). A wide range of in vitro models are currently 
available including organ cultures, primary cultures, immortalized cells, stem 
cells, barrier systems and three-dimensional models (Zucco et al., 2004). 
Organ cultures 
This type of culture maintains both the composition and architecture of 
original tissue in vitro. However, cells remain in culture for a limited period of 
time and vary individually which can lead to problems in replicating the 
experiment. 
Primary cultures 
In this type of cell culture, cells derive from the mechanical and enzymatic 
dissociation from the tissue of origin. Cell population of a primary culture is 
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not homogeneous and can be propagated to a limited number of steps. The 
physiological and metabolic properties of this in vitro model are very similar to 
those found in vivo.  
Immortalized cell lines 
Through the introduction of sequences of DNA tumor viruses, such as SV40, 
Papilloma virus and Epstain-Barr virus, it is possible to obtain immortalized 
cells which undergo cycles of indeterminate replication. Cells retain some 
characteristics of differentiated tissue, and a relative homogeneity; their use 
facilitates the comparison of results from different laboratories. 
Barrier systems 
This culture system enables not only the interactions established in vivo 
between cells to be reproduced in vitro, but also their functional characteristics. 
Barrier systems are used to study epithelia, which are focal points of 
interaction with xenobiotics and nutrients (Fig. 3). 
  
Fig 3: Bicameral system;  (http:// www.corning.com/lifesciences/cell_culture/transwell_permeable_supports.asp) 
 
 
Three-dimensional models  
This type of cell culture maintains cellular interactions and the relationship 
between structure and function. Three-dimensional models make use of 
different substrates and the culture can be homotypic or heterotypic. This 
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system enables the main cellular functions to be maintained for a limited 
period of time. 
 
2.2.3 In vitro models to study antioxidants 
The antioxidant activity of pure compounds, food, feed, and dietary 
supplements has been extensively studied and numerous analytical approaches 
and assay models have been developed, involving various systems from simple 
chemical assays to animal models and human studies. There is evidence that 
food/feed antioxidants and antioxidant supplementation may protect against 
oxidative stress-induced diseases. 
The properties and sensitivity of the cells and their growth status are critical 
factors that affect the evaluation of antioxidant activity. In addition, cellular 
response to antioxidant components is quite complex, depending on the 
component, exposure dose, and time. Several cell types have been used to set 
up cell-based bioassays for assessing the antioxidant activity of foods and 
dietary supplements with wide concentration ranges. 
Primary isolated rat hepatocytes have been used to evaluate the protective 
effects of melanoidins in adriamycin-induced oxidative stress (Valls-Belles et 
al., 2004). Fusi et al. (2010) evaluated the protective effects of α-tocopherol in 
ochratoxin A (OTA) induced oxidative damage in primary porcine ﬁbroblasts. 
These researchers found a different sensitivity of ear and embryonic 
ﬁbroblasts both to oxidative damage and antioxidant treatment. Primary cells, 
isolated from human or animal tissue, could be a good cell-based model as 
they retain the majority of the in vivo functionality; however they survive and 
maintain their differentiation for only a few days in cell cultures. If the 
primary cells are chosen, it is important to consider that they are usually 
derived from different individuals in each test; consequently, the 
reproducibility of results may differ significantly from one test to another. 
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When phenotypic screens using primary cells are included in cell-based 
bioassays, a constant supply of biologically homogenous cells is thus necessary 
to support a large scale study. Moreover, the isolation procedure for primary 
cell culture preparation can reduce the survival of the cells and cause changes 
in gene expression, metabolic activity, and the levels of enzymes involved in 
the oxidant and antioxidant systems.  
Halliwell (2003) discusses in detail how “culture shock” can affect cell survival 
and metabolic activity, and concludes that the cells which do survive appear to 
be those that have adapted rapidly, and are probably not representative of the 
original cells harvested from a tissue.  
Other types of cells that can be used in antioxidant testing are immortalized 
cell lines. It is fundamental that the cell lines show no altered functional 
response to oxidative stress. A cell line basically comprises a phenotypically 
and genetically uniform population of individual cells that have been derived 
from a single tissue. Cell lines are robust, grow, and divide easily in culture, are 
simple to handle and may provide a good platform for cell-based assays. The 
availability of a wide number of human and animal cell lines with diverse 
genotypes and tissue-origins provides broad potential models for the study of 
various biological processes. 
Baldi et al. (2004) evaluated the protective effects of α-tocopherol in OTA 
induced oxidative damage. A panel of five well characterized human and 
animal cell lines, SK-N-MC (human neuroblastoma), MDCK (Madin Darby 
canine kidney), AML-12 (mouse liver hepatocytes), LLC-PK1 (pig kidney), 
and BME-UV1 (bovine mammary epithelium), were successfully used to 
investigate the effect of α-tocopherol on ROS production on OTA-treated 
cells. A signiﬁcant difference in cell sensitivity was also found, with BME-
UV1 and MDCK being the most sensitive cell lines. Although the choice of 
the most suitable cell-based assays is key in the correct evaluation of the 
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antioxidant activity of food/feed compounds, there are other important 
elements to be considered: choice of biomarkers, endpoint, effect of cell 
culture medium and environment, and the cell culture system selected. The 
transition from research models to test models for cell-based bioassays still 
needs the optimization, standardization and validation of analytical protocols. 
Thus, despite the fact that antioxidant activity has been demonstrated in vitro, 
it has not always been demonstrated in vivo. This reflects the limitation and 
complexity of human clinical studies where there are several confounding 
factors present such as sex, age and total antioxidant status (Cheli and Baldi, 
2011). 
 
 
 
 
2.2.4 In vitro models to study milk bioactive compounds  
When assessing the bioactive compounds of milk, it is important to know the 
physiology of the organ that produces the milk and how this organ and its 
cells respond to both physiological and pathological stimuli. If the object of 
the study is Lactoferrin this aspect is important as mammary epithelium cells 
produce Lf and, at the same time, are sensitive to its action. Understanding 
the origin of bioactive compounds and their role in nature may influence the 
research into how this nutraceutical can improve the health of consumers. 
Studies on cellular responses to physiological and pathological conditions 
generally focus on the plasmin-plasminogen system since it is one of the main 
cellular response systems that play a pivotal role in the mammary gland, both 
in development and defense mechanisms (Baldi et al., 1996; Politis 1996; Cheli 
et al., 1999, Cheli et al., 2003). 
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The mammary gland is a complex organ that undergoes continuous changes. 
Thus the choice of the most efficient model to study mechanisms in vitro that 
regulate the production of milk and bioactive compounds is very important, 
because the type of cell and the culture system adopted need to enable the 
suitable phenotype to be maintained. In addition, the cells need to be able to 
synthesize the various milk constituents and respond to lactogenic stimuli. 
The transition from undifferentiated epithelial cells in the active growth phase, 
isolated from pregnant or not yet mature animals, to differentiated cells that 
are able to synthesize milk protein has been achieved in differentiated 
cultures. Epithelial cells are characterized by a high degree of polarization and 
compartmentalization of milk protein. These features are essential requisites 
for the mammary gland to function properly. Established bovine mammary 
epithelial cell lines, well characterized and with the ability to synthesize milk 
proteins efficiently, represent a good in vitro model to study the physiology of 
the mammary gland. 
The ability of cells to proliferate or maintain a phenotype in vitro is closely 
related with the culture conditions and characteristics of the substrate. Finally, 
the possibility to use a porous insert in a bicameral culture system to grow 
epithelial cells represents an interesting in vitro system. Primary cultures of 
epithelial cells of the mammary gland cultured from inserts maintain a high 
degree of functional differentiation, presenting a polarized secretion of milk 
proteins (Claudon et al., 1997). 
MAC-T cell lines, BME-UV and BME-UV1 are some of the in vitro models 
used to study the biology of the mammary gland of ruminants. 
MAC-T cells maintain the morphological characteristics of the mammary 
epithelium in vitro, and are able to secrete milk proteins (Huynh et al., 1991). 
This cell model has been widely used to characterize the role of various 
growth factors or inhibitors in the growth of bovine mammary epithelial cells 
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or to study the interaction of pathogenic bacteria with bovine mammary 
epithelial cells. 
Studies on this cell model have helped to clarify the role of 'IGF-I as a 
mitogen factor (Zavizion et al., 1995). The growth of these cells, however, 
seems to be inhibited in the presence of molecules such as Lf (Hurley et al., 
1994) and α-lactalbumin (Rejman et al., 1992). 
These studies also found that the cells of the line MAC-T when grown in the 
absence of both serum and proteins were able to produce uPA, uPA 
inhibitors and receptors uPA. 
In addition to the obvious advantages of choosing this cell line in studies on 
the metabolism and  response mechanisms of the epithelial cells of the bovine 
mammary gland, there are also disadvantages: it is not a homogeneous line 
and, if the aim is to clarify the mechanisms that involve EGF as a factor that 
influences cell growth, this cell line is not sensitive to the EGF action 
(Woodward, 1994). 
Zavizion et al. (1996b) from the University of Vermont obtained two cell 
lines, BME-UV1 and BME-UV2, which are able to synthesize low levels of α-
lactalbumin and as1-casein. Cells of the BME-UV line express not only the 
typical functional and biochemical markers of mammary epithelial cells, but 
also the morphology "cobblestone" of such cells. 
Such cells form desmosomes and show cytoplasmic cytokeratin fibrils. When 
grown on plastic, they take on a polygonal morphology, while on collagen 
they exhibit morphology at Column and a dome structure, typical of this type 
of epithelial cells in vivo. Furthermore they form long cytoplasmic projections, 
which allow contact between cells to be established. 
The BME-UV line was obtained by the microinjection of a plasmid, of clones 
of epithelial cells containing antigen SV-40 large, derived from the enzymatic 
dissociation of the breast tissue (Zavizion et al., 1996b). These authors were 
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the first to report the use of microinjection to immortalize bovine epithelial 
cells for. In fact previously this method had been used to immortalize 
mammary cells derived from humans (Heim et al., 1995). 
 
 
Fig. 4: BME-UV1 cells aquired by Image Vision (Media Cybernetics, OM 40X) 
 
Thus the BME-UV1 cell line (Fig. 4) is a good in vitro model to study both 
tissue remodeling events and Lf action. In fact BME-UV1 is sensitive to Lf 
action and is able to synthesize α-lactoalbumin and αs1-casein as well as 
express the components of the plasmin-plasminogen system. 
Naturally, the immortalized cell lines are only one of the models available for 
in vitro studies on ruminants; for studies to assess the synthesis of milk fat the 
primary cell lines of mammary gland are the most widely used.  
For example, bovine and goat mammary gland cell cultures were used in 
studies to estimate the possibility of changing the content and the fatty acid 
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profile of milk fat, proving that this cell model is able to maintain in vitro the 
ability to synthesize fatty acids ex novo (Cifrian, 1993). 
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3. Aim of the study 
The general aim of my PhD study was to evaluate nutraceutical effects at a 
cellular level in response to different stress challenges.  
 
In the first section of my thesis, the protective role of α-tocopherol in 
counteracting the cytotoxicity and DNA damage induced by Ochratoxin A 
(OTA) in primary porcine fibroblast cell cultures (ear and embryo), was 
determined by using the MTT assay, LDH release, DNA fragmentation, and 
TUNEL stain (Chapter 4). 
 
The aim of the second section was to evaluate the protective role of bovine 
Lactoferrin (bLf), added to the culture medium, against lipopolysaccharide 
(LPS) cytotoxicity using the established bovine mammary epithelial cell line 
BME-UV1 as an in vitro model of the bovine mammary epithelium. In 
addition, we assessed whether BME-UV1 cells were able to express 
endogenous bLf after in vitro exposure to LPS (Chapter 5). 
 
A further objective of my thesis work was to use cell-based bioassays to 
investigate the plasmin-plasminogen system. This system plays a key role in 
cellular responses, and is involved both in physiological and in pathological 
conditions in the mammary gland. The aim of the third section was to 
determine the effect of growth factors (IGF-1 and EGF) and three hormones 
(insulin, dexamethasone, and prolactin) on the expression of plasminogen 
activator (PA)-related genes (u-PA, u-PAR, PAI-1, PAI-2) and BME-UV1 cell 
proliferation. In addition we investigated the effects of E. coli LPS on cell 
viability, the modulation of cell-associated u-PA activity and the regulation of 
u-PA and u-PAR RNA expression in BME-UV1 cells (Chapter 6). 
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4. -Tocopherol counteracts the cytotoxicity 
induced by Ochratoxin A in primary porcine 
fibroblasts 
 
4.1 Introduction 
Oxidative stress can be defined as an imbalance between oxidants and 
antioxidants (Cheli and Baldi, 2011). Normally the body is protected from 
oxidative damage by a wide range of antioxidants, forming an integrated 
defence system (Miller et al., 1993). As such, antioxidants can be broadly 
defined as any substance that delays, prevents or removes oxidative damage to 
target molecules (Halliwell and Gutteridge, 2007). Cell antioxidant system 
includes preventive and scavenging molecules and enzymes that remove 
superoxides and peroxides before they react, and chain breaking antioxidants 
as vitamin E, C, carotenoids, that interrupt the free radical chain reaction 
cascades initiated by ROS. Some of these antioxidants share both the 
activities. Under physiological conditions, the presence of antioxidants that 
function at cytosolic, extracellular or lipophilic (membrane lipids) phases can 
handle the ROS produced during oxygen metabolism by effectively 
neutralizing and eliminating them and play an essential role in maintaining 
tissue integrity (Sordillo and Aitken, 2007). When ROS are generated in excess 
or cellular level of some antioxidant decreases, as typically occurs in ageing or 
during diseases, the free radicals produced can overwhelm the protection 
system and become toxic to the cell reacting with and damage many biological 
molecules, such as proteins, lipids and DNA (Cheli and Baldi, 2011). 
Nutrition can have a major influence on pro-oxidant/antioxidant balance, 
since several components of the antioxidant system are micronutrients 
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(vitamin C, E, carotenoids) or require dietary micronutrients (Se and Zn). A 
deficiency of any of these nutrients may affect the antioxidant system 
efficiency, impairing immunity status and health. 
In particular, Vitamin E plays a crucial role in protecting cell membranes from 
oxidative stress damages. 
 
4.1.1 Vitamin E structure 
Vitamin E was discovered in 1922 by Evans and Bishop (1922); it was 
identified as a micronutrient essential for reproduction in rats. In 1936 the 
same researcher isolated the active substance of vitamin E and called it 
tocopherol (Wang et al., 1999). On the same year two compounds with 
vitamin E activity have been identified and were designated α- and β-
tocopherol (Evans et al., 1936). Two other forms of tocopherol were also 
discovered γ and δ (Emerson et al., 1937; Stern et al., 1947) in addition to the 
tocotrienols (Pennock et al., 1964). 
The prefixes α, β, γ and δ are used to distinguish the form of both 
tocopherols and tocotrienols. Number and position of the methyl substituent 
attached to the chromanol ring allow to characterise α-, β-, γ- and δ-isomers 
(Wang et al., 1999). 
When α-tocopherol is synthesised chemically, a racemic mixture of all 8 
possible isomers of α-tocopherol in equimolar concentrations is produced 
(synthetic form, also referred as all-rac α-tocopherol and historically labeled 
dl-α-tocopherol), with four stereoisomers showing a 2R configuration (RRR, 
RRS, RSS, RSR, having R configuration at position 2’ of the phytyl tail) and 
four stereoisomers possessing a 2S configuration (SRR, SSR, SRS, and SSS, 
having S configuration at position 2’ of the phytyl tail, Figure 5). Among 
possible different forms of α-tocopherol, RRR α-tocopherol is the only 
isomeric form of vitamin E produced by plants (natural form, historically 
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labeled d-α-tocopherol) and is therefore the only one naturally present in 
feedstuffs. 
 
 
Fig 5. Natural and synthetic vitamin E. 
 
The different stereoisomeric forms of vitamin E have different bioavailability 
and different biological activity in humans and animals, with RRR isomer 
having a greater biopotency than the synthetic form on a molar or mass basis. 
Several factors such as structural diversity of compounds with antioxidant 
activity, food matrix structure and antioxidants relative proportions in 
standard diets influenced antioxidant bioavailability. 
 
4.1.2 Vitamin E absorption and metabolism 
Hydrophobic nature of vitamin E requires special transport mechanisms to go 
through aqueous environment of body and cells. Vitamin E is absorbed in 
small intestine where it is emulsified with fat-soluble components of the food. 
Following action of bile salts and pancreatic juices vitamin E is incorporated 
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into mixed micelles which are absorbed by brush border membrane of 
enterocytes by passive diffusion. 
Into Golgi of enterocyte, α-tocopherol is packaged into chylomicrons together 
with triglycerides, phospholipids, cholesterol and apolipoproteins; 
chylomicrons are excreted by exocytosis and they reach blood stream via 
lymphatic system (Azzi et al., 2000; Brigelius-Flohé et al., 1999; Rimbach et al., 
2002). 
In blood stream, chylomicrons gain apolipoproteins C and E from HDL; 
apolipoprotein C actives endothelial lipoprotein lipase (LPL) in target tissue 
such as adipose tissue and muscle. LPL takes part in catabolism of 
chylomicrons by hydrolyzation of triglyceride forming remnants that can be 
absorbed by hepatic cells by receptor-mediated endocytotic processes. 
While uptake of vitamin E from food in small intestine involves an unspecific 
mechanism, in liver hepatic cells own a specific transport protein (α-TTP) that 
allow they to uptake α-tocopherol excluding both other form of natural and 
sintetic tocopherol. 
α-TTP preference for α form of tocopherol and its proportional enrichment 
in plasma lipoproteins has been observed in rats, guinea pigs, salmons, 
monkeys and in humans (Traber et al., 2004). 
Since α-TTP is a specific transport protein for alpha form of tocopherol, it is 
recognized to be the most important determinant of plasma tocopherol level 
and mutation of gene for α-TTP could reduce plasma level of α-tocopherol. 
Although Vitamin E is generally studied in order to its antioxidant function, it 
seems that it can influences various signaling cascades at the cellular level by 
inhibiting protein kinase C (PKC) that has an important role in the cell signal 
transmission. Some studies (Azzi et al., 2000; Brigelius-Flohé et al., 2002) 
suggest that α-tocopherol may control many cellular events by the regulation 
of PKC at the gene level. 
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4.1.3 Antioxidant activity of vitamin E 
Vitamin E is the most important lipid-soluble antioxidant and is an integral 
component of all lipid membranes. It acts as a radical scavenger and serves to 
protect lipid membranes from attack by ROS. In particular polyunsaturated 
fatty acids (PUFA) of membranes are vulnerable to attack by ROS, which can 
initiate a chain reaction of lipid peroxidation that destroy cell membrane.  
Due to its hydrophobicity, vitamin E tends to position itself either into tissue 
lipids or in hydrophobic domains of molecules like lipoproteins, in fact, in 
cellular environment; vitamin E is localized in cell membranes and 
lipoproteins. In these sites vitamin E can explicate its antioxidant role against 
free radical action. 
Vitamin E peroxyl radical scavenging function allows cell to maintain both 
integrity and bioactivity of long-chain polyunsaturated fatty acids. These 
bioactive lipids are important for membrane plasticity and are signaling 
molecules. Change in their amounts or in their oxidation products can modify 
cell response and balance between cell and environment (Traber et al., 2007). 
Free radicals damages can be reversible or irreversible and they are addressed 
to target molecules such as DNA, lipids and proteins. High speed generation 
of ROS is due to their ability to propagate the reaction started with a single 
initiating radical species to a wide number of target molecules so antioxidant 
action speed is very important to stop ROS generation and its damages. 
Cells own antioxidant defense mechanisms that are normally able to detoxify 
the reactive intermediates or to repair damages. Imbalance between ROS 
production and biological antioxidant system implies oxidative stress. 
Differently from other cellular antioxidants, α-tocopherol activity is 
nonenzimatic and fast.  
Oxidation of lipid is a process that involves a free radical chain reaction. 
Chain propagation of lipid oxidation is allowed by reaction between a lipid 
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peroxyl radical and a lipid target. Lipid peroxyl radical takes away a hydrogen 
atom from the lipid target producing a lipid hydroperoxide and a carbon-
centred lipid radical. The latter one reacts with molecular oxygen to generate 
another lipid peroxyl radical starting the chain reaction (Wang et al., 1999). 
Vitamin E does its antioxidant role by scavenging the peroxyl radical and 
blocking free radical propagation. Reaction between lipid peroxyl radical and 
α-tocopherol results in α-tocopheroxyl radical and lipid peroxide; following 
ascorbic acid can reduce α-tocopheroxyl radical back to α-tocopherol by 
donating electrons (Wang et al., 1999; Azzi et al., 2000). 
In vitro studies have shown that scavenging action of α-tocopherol to peroxyl 
radical is faster than action of this one to lipid target (Wang et al., 1999). 
 
4.1.4 Antioxidant activities in vitro measured 
Measuring production of ROS following exposure to oxidative stimuli, it is 
possible to evaluate the ability of Vitamin E to scavenge free radicals and, 
consequently, protects the membrane of cell. 
Of the many environmental oxidative stressors, xenobiotics, like Ochratoxin 
A (OTA), represents a cause of ROS generation that may compromise 
antioxidant defense mechanisms. OTA is a mycotoxin produced by Aspergillus 
and Penicillum species, it is present in food and feedstuffs and it is responsible 
for ROS formation. International Agency for Research on Cancer considered 
it as a possible carcinogenic (group 2B) to humans. The scientific panel on 
contaminants in the food chain of the European Food Safety Authority 
released an opinion related to OTA in food (EFSA 2006), in which it 
summarized the major information on OTA related to human health but also 
indicated the susceptibility of pigs and other animals to OTA. 
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In porcine species OTA contamination is responsible for acute, subchronic 
and chronic intoxications determining financial losses in the agriculture and 
food industry (O’Brien et al. 2005). 
At the cellular level OTA can act directly or by indirect mechanisms and it 
involves various mechanisms of action: lipid peroxidation, disruption of 
calcium homeostasis, inhibition of protein synthesis, mitochoindrial 
respiration and DNA damage (Ringot et al., 2006). At the cellular level α-
tocopherol acts as an antioxidant terminating the chain of events of oxidative 
processes by donation of its phenolic hydrogen to chain propagating lipid 
peroxyl radicals, resulting in the enhanced formation of the less reactive α-
tocopheroxyl radical (Zhang and Omaye, 2001). 
In vitro studies (Baldi et al., 2004; Fusi et al., 2008) have investigated that α-
tocopherol has protective activities against OTA reducing ROS production. 
Particularly, Baldi et al. (2004), using BME-UV1 cell line susceptible to OTA 
cytotoxicity (LC50=0.8 µg/ml at 24 h), have tested a protective effect of α-
tocopherol against OTA stimulus. Three hours pre-incubation with 
antioxidant significantly (P < 0.05) ameliorated the OTA-induced reduction in 
cell viability and significantly (P< 0.05) decreased ROS production concluding 
that: (1) oxidative stress is an important factor in OTA cytotoxicity and (2) 
supplementation with α-tocopherol is able to counteract the short-term 
toxicity of OTA. 
In the same study researchers have used other cell lines to test α-tocopherol 
ability to protect cells against OTA action finding that α-tocopherol 
significantly inhibited OTA-induced ROS production and this inhibition was 
concentration-dependent.  
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4.2 Aim  
Under the light of the effects of OTA on porcine species, as described above, 
and considering primary cell culture as a good cell-based model since primary 
cells retain most of the in vivo functionalities, the aim of this part of my PhD 
was to determine the toxic effects of OTA in primary porcine fibroblast cell 
cultures by using the MTT assay, LDH release, DNA fragmentation and 
TUNEL stain. At the same time another purpose of the study was to 
determine the contribution of α -tocopherol in counteracting the cytotoxicity 
and DNA damage induced by OTA in the same in vitro model. 
 
4.3 Materials and methods 
4.3.1 Chemicals 
Ochratoxin A, racemic α-tocopherol, penicillin, streptomycin and 3-(4,5- 
imethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) were purchased 
from Sigma-Aldrich (St. Louis MO, USA). Dulbecco’s Minimum Essential 
Medium (DMEM) and glutaMax were obtained from Gibco (Invitrogen); and 
FBS (South America) from Bio Whittaker. Ochratoxin A was dissolved in 
methanol to obtain a stock solution of 5000 µg/mL. According to the data 
obtained in preliminary studies (Baldi et al., 2002; Cheli et al., 2003), racemic 
α-tocopherol was dissolved in absolute ethanol to prepare a stock solution of 
10 mM. 
These stock solutions were used for further dilutions in DMEM containing 
0.6% FBS to obtain the final concentrations of each compound.  
 
4.3.2 Cell culture  
In this study, primary porcine fibroblasts isolated from embryo and from ear 
were used. Fibroblasts were grown in monolayers in 75-cm2 plastic culture 
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flasks (Nunclon, Nunc Denmark) in Dulbecco’s Minimum Essential Medium 
(DMEM) supplemented with 1% glutaMax, 2500 I.U./mL penicillin, 2.5 
mg/mL streptomycin and 10% FBS. Primary fibroblasts were cultivated in a 
humidified atmosphere with 5% CO2 at 37 °C and split 1:4 once a week. In all 
experiments in this study, we used embryonic porcine fibroblasts between 
passages 5 and 10 and ear between 5 and 8. All experiments were conducted 
in media containing 0.6% serum, the minimum useful concentration to 
maintain the selected in vitro models.  
 
4.3.3 Determination of the half-lethal concentration and LDH release induced 
by ochratoxin A  
Cells were seeded in 96-well culture plates (3000 cells/well, in 200 μL of 
complete medium) and were cultured for 24 h. A dose–response experiment 
was set up. Fibroblast cultures were exposed to increasing concentrations of 
OTA (0–10 µg/mL) for the following 24 or 48 h. The effects of OTA 
treatments on fibroblast viability were determined using the MTT test. 
Cellular viability was determined using a colorimetric assay based on the 
production of the chromophore formazan from 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide (MTT). Formazan is produced in viable cells 
by the mitochondrial enzyme succinate dehydrogenase. At the end of the 
incubation, the media were removed, the monolayers were washed with PBS 
twice, 150 μL MTT stock solution (5 mg/mL) in PBS was added to each well, 
and the plates were incubated for 3 h at 37 °C in a humidified chamber. To 
dissolve the formazan, 150 μL dimethyl sulfoxide was added to each well, 
after discharging the MTT solution. Absorbance at 540 nm was determined 
on a Biorad 680 microplate reader (Bio-rad, Veenendaal, The Netherlands). 
Cells incubated with culture medium alone, representing 100% viability, were 
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included as negative controls in all experiments. The percentage cytotoxicity 
was calculated as follows: Percentage cytotoxicity = (1 – mean optical density 
in presence of OTA/mean optical density of negative control) × 100. From 
these data the half-lethal concentration (LC50) of OTA for each primary cell 
culture was calculated. Cell membrane damage induced by OTA was detected 
by LDH release using a CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega) as instructed by the manufacturer. Primary porcine fibroblasts were 
seeded in 96-well plates at the density as described above and cultured for 24 
h. Afterward, the cells were exposed to OTA solutions (concentration range: 
0–10 µg/mL) for 24 or 48 h. At the end of the incubation period the media 
were removed and cells washed with PBS twice. 
LDH is a stable cytosolic enzyme released upon cell lysis. The amount of 
LDH was measured with an enzymatic assay using tetrazolium salts in 
conjunction with diaphorase. Briefly, after treatments supernatants were 
removed and centrifuged for 5 min at 1500 × g at 4 °C. 50 μL of each 
supernatant was transferred to a 96 well plate. Cells were lysed by adding 15 
μL of 9% Triton X-100 solution in water per 100 μL of culture medium 
containing 0.6% of serum, followed by incubation for 1 h at 37 °C. Cells 
debris were removed by centrifugation for 5 min at 1500 × g at 4 °C and 50 
μL of each sample was transferred to 96 well plate. Then, 50 μL of LDH 
substrate was added to the supernatants and cell lysates. After incubation for 
30 min at room temperature in the dark, the enzymatic assay was stopped by 
adding 50 mL of 1 M acetic acid and the plate was read at 490 nm using a 
microplate reader. The percentage of LDH release was calculated as the 
amount of LDH in the supernatant over total LDH from both supernatant 
and cell lysate.  
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4.3.4 Detection and quantification of DNA damage induced by ochratoxin A  
DNA fragmentation was measured with the diphenylamine method as 
described by Sandau et al. (1997). Primary porcine fibroblasts were seeded in 
75-cm2 flasks (density: 0.55 × 105 cells/mL) and grown at 37°C in 5% CO2 
for 5 days. At sub-confluence, fibroblasts were incubated with OTA (0–10 
µg/mL) for 24 h. After incubation, the media were removed and centrifuged 
at 1,800 × g for 20 min to collect the detached cells (fraction S). The fraction 
S was subsequently lysed in 5 mL of ice-cold lysis buffer [10 mM Tris, 1 mM 
EDTA (pH 8.0), 0.5% Triton X-100] for 30 min at 4 °C. The remaining 
adherent cells were scraped off the plastic and lysed in 5 mL of ice-cold lysis 
buffer as well. 
After cell lysis, the intact chromatin (fraction B) was separated from DNA 
fragments (fraction T) by centrifugation for 20 min at 13,000 × g. Samples 
were treated with one volume of 25% trichloroacetic acid (TCA), precipitated 
overnight at 4 °C, and recentrifuged 20 min a 13,000 × g at 4 °C, and then the 
supernatants were removed. DNA was hydrolysed by adding one volume of 
5% TCA to each pellet and heating 15 min at 90 °C in a heating block. DNA 
content was quantitated using the diphenylamine reagent. Afterward, 1600 μL 
of DPA solution (in 10 mL glacial acetic acid: 150 mg diphenylamine, 150 μL 
H2SO4 and 50 μL acetaldehyde 16 mg/mL solution) were added to each 
fraction and incubated for 4 h at 37 °C in the dark. The OD600 of each 
fraction (S, B, and T) was determined. The percentage of DNA fragmented 
was calculated as the ratio of the DNA content in the supernatant (T) to that 
in the pellet (B), considering also the quantity released by cells undergoing 
apoptosis and lysis during the experiment. 
Percentage of fragmented DNA = [(S + T)/(S + T + B)] × 100 
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4.3.5 Detection of DNA damage induced by ochratoxin A by TUNEL 
(TdT-mediated dUTP nick end labeling) assay 
Primary porcine fibroblasts were seeded at a density of 0.4 ×105 cells/mL in 
chamber slides, which had two chambers (Nunc Lab-Tek, Nunc, Denmark), 
which were previously coated with a thin layer of poly-L-lysine 0.01% (Sigma) 
to support cellular adhesion. Cells were cultured for 24 h in complete 
medium. Afterward, the media were removed and the fibroblast monolayers 
washed twice with PBS. Based on results obtained from previous assays, 0.6 
µg/mL OTA and the appropriate LC50 (embryonic LC50: 5 µg/mL OTA; ear 
LC50: 1.2 µg/mL OTA) were added to each chamber slide for the following 24 
h. At the end of the incubation, the media were removed and the cells fixed 
with 4% paraformaldehyde at room temperature for 25 min. The TUNEL 
assay was performed using the DeadEnd Colorimetric Apoptosis Detection 
kit (Promega, Madison, WI, USA). The monolayers were washed twice with 
PBS and permeabilized by immersing the slides in 0.2% Triton X-100 solution 
in PBS for 5 min at room temperature. After washing with PBS, cells were 
incubated with biotinylated nucleotide mixture together with terminal 
deoxynucleotidyl transferase enzyme. Horseradish peroxidase–labeled 
streptavidin (streptavidin HRP) was then added to bind to these biotinylated 
nucleotides, which are detected using the peroxidase substrate hydrogen 
peroxide and the stable chromogen diaminobenzidine (DAB). Afterward, to 
visualize and estimate the apoptotic and normal cells, haematoxylin staining 
was performed. Images (20X and 40X) were captured under an Olympus 
BX51 microscope. For each experiment, ~500 cells were counted in randomly 
selected fields, and the percent of TUNEL-positive cells was calculated.  
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4.3.6 Determination of the effect of α-tocopherol against OTA-induced toxicity  
To evaluate the most suitable concentrations of α-tocopherol for interaction 
experiments with OTA, a dose–response curve for this compound was 
established using serial concentrations from the nanomolar to micromolar 
range (data not shown). Cell culture setup and conditions were as detailed 
above. Primary porcine fibroblasts were cultured with LC50 doses of OTA in 
the presence or absence of α-tocopherol (1 nM or 1 µM). Cell viability and 
LDH release after antioxidant treatment were assessed as previously 
described. To determine cell viability, primary fibroblasts were first pre-
incubated for 3 h with α-tocopherol and then exposed to increasing 
concentrations of OTA for 24 or 48 h. Cells were also exposed to antioxidant 
alone or ethanol (the α-tocopherol solvent) alone to evaluate any non-specific 
effects. Inhibition of cytotoxicity was determined by MTT, LDH release, 
DNA fragmentation and TUNEL assays and calculated as the percentage 
inhibition (percentage cytotoxicity OTA–percentage cytotoxicity of (OTA + 
antioxidant)).  
 
4.4. Statistical analysis  
The data are expressed as means ± standard errors (SE). At least three 
replicates at each incubation time were performed, and all the experiments 
were performed twice. Obtained data were analyzed by one-way ANOVA 
(General Linear Models Procedure); Duncan’s post-hoc multiple range test 
was used, with P ≤ 0.05 considered statistically significant.  
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4.5. Results  
4.5.1 Cytotoxic effect and LDH release induced by ochratoxin A 
We first investigated the LC50 of OTA after 24 h and 48 h of treatment in ear 
and embryo porcine fibroblasts and found that the LC50 differed between the 
two cell types. At all incubation times, the fibroblasts derived from ear were 
the most sensitive to OTA cytotoxicity (LC50 = 0.93 µg/mL after 24 h; LC50 = 
0.92 µg/mL after 48 h), while fibroblasts isolated from the embryo showed a 
time-dependent sensitivity (LC50 = 4.24 µg/mL after 24 h, 2.34 µg/mL after 
48 h). Figure 6 shows the data on LDH release by primary porcine ear and 
embryo fibroblasts in the presence of several concentrations of OTA at 24 
and 48 h of incubation. In both cell types, LDH release increased significantly 
(P < 0.01) at OTA concentrations above 2.5 µg/mL after 24 and 48 h of 
incubation.  
 
 
Fig. 6: Concentration-dependent release of LDH into culture media by primary porcine ear and embryo fibroblasts 
after 24 h (A) and 48 h (B) exposure to OTA concentrations. 
 
 
4.5.2 Detection and quantification of DNA damage induced by ochratoxin A  
OTA was able to induce DNA fragmentation in both primary porcine 
fibroblast cultures, as measured by a diphenylamine assay. After 24 h of 
incubation, in the absence of OTA (control), 14% DNA fragmentation in 
A B 
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both primary cultures occurred. A dose-dependent fragmentation in fibroblast 
cultures, due to the exposure to increasing concentrations of OTA, was found 
(Figure 7). At 0.6 µg/mL of OTA, the DNA fragmentation percentages of 
both types of fibroblasts were similar to control levels. Exposure to high 
OTA concentrations (2.5, 5, or 10 µg/mL) led to increasing percentages of  
DNA fragmentation in the two types of cells. At 10 µg/mL of OTA, DNA 
fragmentation was 92% in fibroblasts isolated from ear and 66% in embryonic 
fibroblasts.  
 
Fig 7: DNA fragmentation in primary fibroblasts 24 h post–OTA stimulation. 
 
Cell death may occur by several mechanisms. It is well known that LDH 
release is a marker of cellular membrane damage, while DNA fragmentation 
measurements give an indication of the percentage of fragmented DNA out 
of the total nuclear DNA of cultured cells. A comparison of DNA 
fragmentation with LDH release after 24 h of OTA exposure is shown in 
Figure 8. After 24 h exposure to 0.6, 5, or 10 µg/mL OTA in both fibroblast 
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cultures, we observed that the changes in DNA fragmentation and LDH 
release were almost proportional.  
 
 
 
Fig 8: Comparison of DNA fragmentation and LDH release in fibroblasts cultures after 24 h of exposure to 0.6, 2.5, 
5, or 10 µg/mL OTA. The solid line indicates an equal percentage of DNA fragmentation and LDH release. During 
necrosis, the experimental values should be close to this line (Gekle et al., 2000). In the presence of the selected OTA 
concentrations, in both cell cultures the experimental values indicated proportional changes in DNA fragmentation 
and LDH release. 
 
4.5.3 Detection of DNA damage by TUNEL assay  
In a series of experiments, we examined the effect of OTA exposure on 
fibroblast cultures using the TUNEL assay. Figure 9 shows representative 
photos of ear fibroblast morphology and nuclear stains in cells maintained in 
culture and exposed to OTA for 24 h. In the absence of OTA, the uniformity 
of monolayers, the typical fibroblast shape and cell-cell interactions in cultures 
were evident in fibroblasts from both sources tested. Only 4% and 6% of 
nuclei were apoptotic in cultures of primary ear and embryonic fibroblasts, 
respectively. The percentage of dark-brown apoptotic nuclei in primary 
fibroblasts, isolated from ear and embryo, co-incubated for 24 h with 0.6 
µg/mL of OTA, were 32% and 16%, respectively. In both ear and embryo 
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fibroblast cultures after 24 of OTA incubation above LC50, monolayers were 
completely destroyed and cell debris were evident in all the microscopic fields. 
 
Fig 9: Representative photographs of selected fields of TUNEL-stained ear fibroblasts are shown. The TUNEL-
positive nuclei, indicating apoptotic cells, are stained brown (black arrows), while the vital nuclei are stained violet 
(haematoxylin). (a) Ear fibroblasts in culture for 24 h (no OTA). (b) Ear fibroblasts treated with 0.6 µg/mL OTA for 
24 h. (c) Ear fibroblasts treated with 1.25 µg/mL OTA for 24 h. (d) Ear fibroblasts treated with 1 nM α-tocopherol 
and 0.6 µg/mL OTA for 24 h. Bars = 200 µm. 
 
4.5.4 Effect of α-tocopherol on ochratoxin A–induced toxicity 
The inhibitory effects of α-tocopherol on OTA cytotoxicity were evaluated 
using several toxicity assays: MTT test, LDH release, DNA fragmentation and 
TUNEL assays. Pre-treatment with α-tocopherol (1 nM) for 3 h, followed by 
OTA exposure for 24 h, significantly (P < 0.01) reduced the loss of cell 
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viability induced by OTA in both in vitro models, as determined by the MTT 
test: by 17.5% in ear fibroblasts exposed to 0.3 µg/mL OTA and by 14.7% in 
embryonic fibroblasts exposed to 0.6 µg/mL OTA. Treatment with 1 µM of 
antioxidant solution did not affect OTA toxicity. After 48 h, α-tocopherol at 
both concentrations was unable to counteract the OTA-induced cytotoxicity 
in either cell type. The data on LDH release induced by OTA after 3 h pre-
incubation with 1 nM or 1 µM α-tocopherol in fibroblast cultures are shown 
in Figure 10. At 24 h of incubation, in ear fibroblasts, α-tocopherol at both 
concentrations significantly (P < 0.01) decreased LDH release when OTA was 
present at 0.3–0.6 µg/mL. In embryonic fibroblasts at both concentrations of 
antioxidant, LDH release in the presence of all OTA concentrations used was 
significantly reduced (P < 0.05) compared to control cultures (OTA only). 
After 48 h of co-incubation with tocopherol and OTA, no difference in LDH 
release in either cell type was detected. These data confirm that the origin of 
the cells can not only explain the response to OTA stimuli, but also the 
sensitivity to antioxidant response. 
 
 
 
Fig 10: Effect of α-tocopherol on Ochratoxin -A-induced LDH release in primary porcine fibroblasts at 24 h. Values 
are means, with standard errors of the mean represented by vertical bars.  A: Ear fibroblasts; B: Embryonic 
fibroblasts 
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The effects of 3 h pre-incubation with 1 nM or 1 µM α-tocopherol on OTA-
induced DNA fragmentation in primary fibroblasts is shown in Figure 11. 
Treatment with 1 nM α-tocopherol resulted in a significant (P < 0.05) 
decrease in DNA fragmentation compared with control incubation (OTA 
only). This decrease was 15% in the presence of 5 µg/mL of OTA in ear 
fibroblasts and 16% in the presence of 10 µg/mL of OTA in embryonic 
fibroblasts. 
 
 
 
Fig 11: Effect of α-tocopherol on OTA-induced DNA fragmentation in primary porcine fibroblasts at 24 h. Values 
are means, with standard errors of the means represented by vertical bars. A: Ear fibroblasts; B: Embryonic 
fibroblasts 
 
The effects of α-tocopherol pre-treatment on DNA fragmentation induced by 
OTA were evaluated by TUNEL assay. In ear fibroblasts α-tocopherol pre-
treatment (1 nM or 1 μM) did not significantly reduce the percentage of 
apoptotic nuclei by 12% and 9%, respectively. A representative photograph of 
ear fibroblasts pre-incubated with α-tocopherol and co-incubated with 0.6 
µg/mL OTA for 24 h is shown in Figure 9(d). In embryonic fibroblasts, α-
tocopherol pre-treatment (1 nM or 1 μM) insignificantly decreased the 
percentage of apoptotic nuclei in the presence of 0.6 μg/mL OTA by 11% 
and 8%, respectively. α-tocopherol was not able to reduce the damage to 
nuclei when OTA concentrations were above LC50 (embryonic: 5 µg/mL 
A B 
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OTA; ear: 1.2 µg/mL OTA), since the cells of treated monolayers detached, 
and cellular debris floated in the observed fields (data not shown). 
 
4.6 Discussion 
The present work has shown an origin-dependent sensitivity to OTA. 
Previous studies have shown different cytotoxic responses to in vitro OTA 
challenges in different cell lines (Baldi et al., 2004). Our results confirm that 
the origin of the cells could explain the response to OTA stimuli, as reported 
by several groups (Schwerdt et al., 2007; Gekle et al., 2005). To date, most of 
the studies have been conducted using epithelial cells originated from several 
mammalian species, but only human fibroblasts were used in some studies 
(Russo et al., 2005; Schwerdt et al., 2007). In order to evaluate membrane 
damage, we have used LDH release as memabrane damage marker. In our 
study, after only 24 h of incubation, the fibroblast cultures showed 
considerable LDH release when OTA was present at concentrations similar to 
the doses used by Russo et al. (2005), indicating early cellular membrane 
damage. Schwerdt et al. (Schwerdt et al., 2007), in their studies on the long-
term effects of OTA on primary fibroblasts, indicated that LDH release in the 
media increased only after five days of exposure to OTA, while Russo et al. 
(2005) reported a significant LDH release after 72 h of OTA treatment. 
As is well known OTA was able to induce DNA fragmentation, our results 
confirm the different sensitivities of fibroblasts to OTA-induced cell damage. 
Russo et al. (2005) report that human fibroblast cultures show DNA damage 
after 72 h of OTA exposure at high concentration. However, OTA 
concentrations lower than the dose used by Russo et al. (2005) revealed that 
these damages occurred earlier and were present after 24 h of OTA exposure. 
The different origins of the cells (human vs. porcine) could explain the 
difference in sensitivity. Moreover, as indicated by O’Brien et al. (2001) the 
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cellular response to OTA toxicity related not only to the amount of the 
mycotoxin that gained access to the cells but also to the individual cell 
tolerance to OTA load. Cell death may occur by several mechanisms. It is well 
known that LDH release is a marker of cellular membrane damage, while 
DNA fragmentation measurements give an indication of the percentage of 
fragmented DNA out of the total nuclear DNA of cultured cells. Based on 
our data, we suggest that the cell death process induced by OTA involved 
both cellular and DNA damage. Gekle et al. (2000), showed that OTA 
exposure induces apoptosis and necrosis in the MDCK-C7 and MDCK-C11 
cells, respectively, as indicated by comparing DNA fragmentation with LDH 
release. 
At the cellular level, OTA toxicity involves various mechanisms of action 
including DNA damage. Although studies conducted by several groups 
(Petrik et al., 2003; Schwerdt et al., 2007; Gekle et al., 2000) indicate the 
apoptotic pathway as the means by which OTA induces toxicity in vivo and in 
vitro, the determination of predominant cell death pathways depends on 
several conditions, such as the experimental model, the dose of toxin and the 
duration of the exposure. The mechanisms and morphologies of apoptosis 
and necrosis are different, but there is an overlap between these two 
processes, in what has been called “necrosis–apoptosis continuum” (Zeiss et 
al., 2003). In fact, it is not simple to distinguish the predominant process, as 
apoptosis and necrosis can occur simultaneously (Elmore et al., 2007). 
Understanding the evolution of cell death in cellular models is critical. 
Therefore, once again, it is important not only to consider the concentration 
and duration of toxin exposure and the cell type, but also to employ multiple 
endpoint assays (O’Brien et al., 2001). 
Taken together, our results indicate that α-tocopherol counteracts the toxicity 
of the mycotoxin OTA. In particular, the pre-incubation with α-tocopherol 
50 
 
reduced LDH release and DNA damage in both fibroblast cultures, thereby 
preserving the integrity of the cells. It is well known that α-tocopherol is 
fundamental to cellular defence mechanisms against endogenous and 
exogenous oxidant agents (Wang et al., 1999). This compound is a peroxyl 
radical scavenger that terminates the free radical chain reaction (Traber et al., 
2007), and its hydrophobic nature stabilises its position in the phospholipid 
bilayer. In fact, in the core of the cellular membrane, as described by Traber 
and Atkinson (Traber et al., 2007), the antioxidant characteristics of α-
tocopherol are due to its H atom donating ability, its position and movements 
in the cellular membrane, and its activity in cytosolic reduction reactions that 
recycle tocopheroxyl radicals, thus preventing lipid peroxidation. As 
demonstrated by Baldi et al. (2004), in MDCK and BME-UV1 cell lines, the 
cytotoxicity and ROS production induced by OTA are reduced by antioxidant 
pre-treatments. In particular, α-tocopherol significantly reduces OTA-induced 
ROS production. This inhibition is concentration-dependent: treatment with a 
higher concentration (10 mM) results in a significantly greater degree of 
protection against ROS production. OTA causes lipid peroxidation and free 
radical formation in mammalian cells. The oxidative metabolism sustained by 
enzymes such as cytochrome P450 enzymes and enzymes with peroxidase 
activities, is responsible for OTA biotransformation and subsequent ROS 
production (Manderville et al., 2008). The OTA toxicity reduction is due to 
the scavenging of lipid hydroperoxil radicals by vitamin E. This is due to the 
increase in the activity of the glutathione peroxidase, which utilizes GSH for 
catalyzing the reduction of hydroperoxides (Grosse et al., 1997). 
Moreover, in BME-UV1 cells, α-tocopherol at two different concentrations (1 
nM and 10 µM) reduces DNA fragmentation (Fusi et al., 2008). In this study, 
antioxidant pretreatment resulted in a reduction of DNA fragmentation by 2–
5% in the presence of 0.6–2.5 µg/mL OTA. Schaaf and co-workers (Grosse 
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et al., 1997), in their studies on oxidative damage and free radical generation 
induced by OTA, observed that α-tocopherol at micromolar concentrations 
does not prevent the loss of cell viability in cultured renal cells. As described 
by Azzi (2007), the effect of α-tocopherol depends on the oxidative 
environment in which it is active. This interaction allows α-tocopherol to act 
as a sensor, monitoring the cellular environment through concentration 
changes and transferring the information from the membrane to the nucleus. 
The effects of α- tocopherol on protein kinase C and the other molecular 
signaling pathways, as suggested by Fazzio et al. (1997), could vary, 
considering the cell-specific pathways of cellular proliferation in which 
vitamin E can act. 
Primary porcine fibroblast cultures offer new in vitro opportunities to study 
OTA cytotoxicity and the role of α-tocopherol in counteracting the several 
types of damage induced by this mycotoxin. OTA cytotoxicity developed 
through several mechanisms of action. The cellular inhibition associated with 
the LDH release and DNA fragmentation induced by OTA showed different 
sensitivities in the two fibroblast cultures. α-Tocopherol treatments could 
reduce the damage induced by OTA at different cellular levels. Our results 
point to the conclusion that the use of α-tocopherol offers new strategies to 
reduce OTA cytotoxicity, supporting its defensive role in the cell membrane 
and its multiple functions in cellular metabolism. 
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5. Evaluation of the protective effect of bovine 
lactoferrin in a bovine mammary epithelial cell 
line 
 
5.1 Introduction 
Milk has a composition that would be able to give the newborn everything he 
needs to grow and develop properly in the first months of life. Milk, in fact, 
provide not only proteins, fats and nutrients needed for growth, but also a 
number of biologically active proteins, provided also by colostrum, involved 
in ensuring the development of the neonate and his state of health. Among 
these active proteins lies lactoferrin (Lf) an 80 kDa iron-binding glycoprotein 
that is a member of transferrin protein family and shows high homology 
among species. 
Lf is a multifunctional protein that is involved in a wide variety of 
physiological functions ranging from regulation of iron absorption to 
antimicrobial activity. 
Because of the multiple beneficial functions of Lf, it is considered as a 
“nutraceutical protein” (Vogel, 2012). Lf has been used for clinical trials and 
industrial applications, whose first application was in infant formula but 
currently it is added to immune system-enhancing nutraceuticals, cosmetics, 
pet care supplements, drinks, fermented milks (Garcìa-Montoya et al., 2012). 
The first to isolate Lf from bovine milk were Sorensen and Sorensen in 1939, 
afterwards three independent laboratories (Groves et al., 1960; Johanson et al., 
1960; Montreuil et al., 1960) concluded that this protein was the main iron 
binding protein in human milk.  
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As a bioactive component of the mammary secretions, Lf is endowed with 
modulator roles and protective functions for the newborn, and its biological 
activity affects the maternal mammary gland as well (Baldi et al., 2005b; 
Pecorini et al., 2005; Pecorini et al., 2009). 
Lf is produced in mammalian species such as human and cow, by glandular 
epithelial cells. This glycoprotein is abundant in human colostrum with an 
amount major of 7 g/L and approximately 1-2 g/L in mature milk (Hu et al., 
2012). It was also found in several external mucosal secretions, including 
saliva, nasal and bronchial secretions as well as in bodily fluids such as blood 
and plasma. Several studies have suggested that Lf can be classified as an 
acute-phase protein because of high concentration in the blood during most 
inflammatory reactions, infection, and excessive intake of iron and tumor 
growth (Adlerova et al., 2008). In fact it has been shown that Lf is able to 
bind iron ions even at low pH, this characteristic is important on the site of 
infection and inflammatory where pH may decrease fewer than 4.5. In this 
situation Lf can prevents bacterial proliferation binding iron release from 
transferrin. Several studies have shown that some of the Lf’ functions are not 
connected with its ability to bind iron (Adlerova et al., 2008) but are mediated 
by the interaction with different cellular structure such as lipopolysaccharides , 
proteoglycans and cell-type receptors (Puddu et al., 2010). 
 
5.1.1 Structure of Lactoferrin 
Metz-Boutique et al. (1984) have discovered the molecular structure and 
amino acid sequence of human Lf. They have classified it as a member of the 
transferrin family owing to its identity of 60% with serum transferrin.  
Baker and Baker (2005) have analysed three-dimensional configuration of Lf 
by crystallographic analysis revealing a highly conserved structure with some 
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differences between species. In spite of Lf is considered a member of 
transferrin family differs from it for some of its important properties. One of 
the differences is the biological location: transferrin is mainly located in 
bloodstream while Lf in exocrine secretions. Lf is also able, contrary to 
transferrin, to retain iron binding capacity at low pH (Valenti and Antonini, 
2005). In the intestinal epithelial cells transferrin is located only in cytoplasm 
upon internalization while Lf can be found both in cytoplasm and into the 
nucleus (Ashida et al., 2004). 
Another important feature of Lf that differentiates it from transferrin is its 
bactericidal ability that is linked to its positive charge concentrated in N-
terminus region (1-7 amino acids), in the first helix (13-30 amino acids) and in 
the region that connects the two lobes (Puddu et al., 2010). 
Lf is a polypeptide chain of ca 700 amino acids folded into two symmetrical 
lobes (N and C lobes) that are connected by a hinge region containing parts of 
a α-helix between amino acids 333 and 343 in human Lf (hLf), which provides 
additional flexibility to the molecule (Öztaş Yeşim et al., 2005). 
N and C lobes are composed of α-helix and β-pleated sheet structures that 
create two domains for each lobe called C1, C2, N1 and N2. These domains 
create one iron binding site on each lobe that can bind two ferric ions in 
synergy with the carbonate ion (CO3
2-) (Vogel, 2012). Amino acids involved in 
iron-binding ability are Asp, Tyr and His, whilst Arg is involved in the bond 
with the CO3
2- ion (Fig.12). 
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Fig. 12: Binding between Lf and Fe (Baker and Beker, 2009) 
 
Although Lf binds Fe2+ or Fe3+ ions, it has also been observed bind other 
ions, such as Cu2+, Zn2+ and Mn2+ and molecules such as  lipopolysaccharides, 
heparin, DNA (Adlerova et al., 2008). The primary structure of Lf shows the 
number and position of Cys residues that allow the formation of 
intramolecular disulphide bridges; Asn residues in the N- and C- terminal 
lobes provide several potential N-glycosylation sites. The bound between Lf 
and Fe3+ is reversibly so Lf can exist in three different forms: apo-Lf (iron 
free), holo-Lf (binds two Fe3+ ions) (Fig.13) and monoferric form (one ferric 
ion) (Adlerova et al., 2008). The last one shows greater resistance to 
proteolysis (Öztaş Yeşim et al., 2005; Drago, 2006).  
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Fig 13: apo-Lf (A)and holo-Lf(B ) (http://chemistry.umeche.maine.edu/CHY431/Conformation3.html) 
 
According to the species, Lf contains a variable numbers of sites for potential 
glycosylation; the degrees of glycosylation determine the resistance to 
proteases or to low pH. 
 
5.1.2 Regulation of Lactoferrin synthesis and its receptor 
Lf is expressed in several tissues in human and in animals. It is expressed both 
constitutively, such as in mucosal surfaces, and inducibly, such as in some 
tissues by external agents (Garcìa-Montoya et al., 2012).  
Kang et al. (2008) have analyzed 60 sequences of Lf genes with full coding 
regions finding that the length of the gene varies from species to species, from 
2055 to 2190 residues, owing to detections, insertions and mutations in the 
stop codon. 
Regulation of Lf synthesis depends of the type of cells that produce it. In the 
case of reproductive tissues the amount of Lf production is under the control 
of estrogens while its production in mammary gland is controlled by prolactin 
(González-Chávez et al., 2009). Endometrium production of Lf is determined 
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by both estrogens and epidermal growth factor. In neutrophils, the Lf 
synthesis happens during differentiation phase and is subsequently stored in 
specific granules. When neutrophils are mature they stopped production of Lf 
that is stored in the secondary granules (Adlerova et al., 2008).  
Synthesis’ regulation of the Lf varies, not only based on the type of cell that 
produces it, but also according to age, gender and in particular changes of life 
of the individual as for example the pregnancy during that there is a 
progressive increase up to 29th week, afterwards concentration of Lf settles at 
a constant level (Adlerova et al., 2008). 
 
5.1.3 Antibacterial activity of Lactoferrin 
Lf has shown anti-bacterial activity against Gram negative, Gram positive and 
some acid-alcohol-resistant bacteria both in vivo and in vitro studies. Lf can 
support the growth of bacteria considered as beneficial with lower iron 
demands such as Lactobacillus spp. and Bifidobacterium spp. (Chih-Ching et al., 
2011) 
Antibacterial function is divided into bacteriostatic and bactericidal activities; 
the first one is linked to the ability of Lf to bind and sequester the Fe3+ ion 
limiting its use by bacteria and consequently inhibiting the growth of them. Of 
course, bacteria have developed mechanisms to counteract iron sequestering 
action from Lf releasing iron chelating compounds called siderophores that 
are able to compete with Lf for Fe3+ ions. Other types of bacteria express 
specific receptors able to of bind Lf changing in its tertiary structure and 
consequently leading to iron dissociation (Adlerova et al., 2008). 
Lf exhibits Gram negative bactericidal activity. Lf, interacting with 
lipopolysaccharides (LPS), is able to damage external membrane of Gram 
negative bacteria. Lf prevent the interaction between LPS and the bacterial 
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cations (Ca2+ and Mg2+) by positive charge of its N-terminal region; this 
interaction causes release of LPS from the cell wall increasing membrane 
permeability damaging bacteria (González-Chávez et al., 2009). 
LPS is the major constituent of the outer membrane of Gram-negative 
bacteria and is considered one of the most potent stimuli of the innate 
immune response. LPS consists of three parts: a core oligosaccharide, a distal 
hydrophilic O side chain and a highly conserved lipid A portion (Puddu et al., 
2010). The last one is responsible for LPS toxic pro-inflammatory properties. 
The interaction between N-terminus of Lf and LPS in addition to damaging 
bacteria is able to potentiate the action of other antibacterial such as lysozyme 
(Garcìa-Montoya et al., 2012). 
Bactericidal action against Gram positive bacterial is based on binding among 
positive charge of Lf structure and anionic molecules present on the bacterial 
surface (for example lipoteichoic acid); this bond reduces negative charge on 
the cell wall favoring antibacterial action of lysozyme (González-Chávez et al., 
2009). Lf has shown ability to prevent the attachment of some bacteria to the 
host cell; probably by binding between oligomannoside glycans of Lf and 
adhesins of bacteria although the mechanism of action is not yet known 
(Drago, 2006). 
 
5.1.4 Lactoferrin in iron metabolism 
The ability of an organism to regulate iron homeostasis is of primary 
importance for its proper function. Whether this micro-nutrient, that is 
required in many metabolic functions, is present in excess, it is toxic, 
promoting microbial growth and cell damages. 
Bindings between lactoferrin and enterocytes are mediated by specific 
receptors and determine Lf degradation with consequent release of Fe3+ ions. 
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A deficiency of intracellular iron may determine an increase in expression of 
specific receptors on the surface of enterocytes and, consequently, an elevated 
absorption of lactoferrin-bound iron (Suzuki et al., 2005). The high 
concentration of Lf in milk, associated with high bioavailability of iron in 
milk, suggests that this glycoprotein is involved in iron absorption in the 
intestine of the newborn. In breast-fed infants there was a better iron 
accessibility than infants on formula; conversely, other researches, have 
observed a higher iron absorption in infants fed lactoferrin-free human milk 
(Adlerova et al., 2008). It seems that Lf property to bound Fe3+ ions is not 
linked mainly to its role in regulating iron homeostasis but to other functions 
of it. 
 
5.1.5 Immunomodulatory and anti-inflammary activity 
Wakabayashi et al. (2006) have conducted a study on the expression of 20 
immune-related genes in the small intestine of mice fed bovine Lf (bLf) (2.5 
g/Kg). They have observed that it can modulate the expression of these genes 
by both specifically and non-specifically mechanisms. 
Thanks to its ability to bind iron and interact with target cells and molecules, 
Lf is considered a modulator of the innate and acquires immune system 
(Legrand et al., 2006). On the one hand the bound between positive charge of 
Lf and negatively charge of molecules on the surface of some immune system’ 
cells strengthen the immune response supporting proliferation, differentiation 
and activation of immune system cells. On the other hand Lf has shown an 
anti-inflammatory action, in fact its ability to bind components of bacteria cell 
walls such as LPS allow it to prevent the development of inflammation 
(Adlerova et al,. 2008). 
Lf has shown anti-inflammatory activity by the inhibition of pro-inflammatory 
cytokines such as interferon-gamma, tumor necrosis factor-alpha and 
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interleukin (IL)-1β, IL-2 and IL-6. At cellular level, Lf increases number of 
natural killer cells, boost the recruitment of polymorphonuclear cells in the 
blood, induces phagocytosis and can modulate the myelopoietic process 
(González-Chávez et al., 2009).  
Some studies (Legrand et al., 2004; Öztaş Yeşim et al., 2005) have shown that 
Lf can activates different signaling pathways by be transported into the 
nucleus and bind DNA, activating different signaling pathways. 
Furthermore, since iron is a catalyst for the production of reactive oxygen 
species (ROS), Lf binding iron action can reduce the harmful influence of  
ROS produced by leukocytes during inflammation (Adlerova et al., 2008; 
Ward et al., 2005). 
In addition to Lf antimicrobial activity, is well-known its antiviral activity 
against wide-range of RNA and DNA viruses infected both humans and 
animals and its antifungal activity against for example Candida spp. 
 
5.1.6 Enzymatic activity 
Lf has been shown an enzyme-like activity. Among milk proteins, Lf has 
shown the highest levels of amylase, DNAse, RNAse and ATPase activities 
(Garcìa-Montoya et al., 2012). Lf enzyme-like activity seems to be attributed 
to: the multiple isoforms of this protein, degrees of glycosylation; tertiary 
structure; and the degree of oligomerisation (González-Chávez et al., 2009). 
 
5.1.7 Bioactive peptides derived from lactoferrin 
By digestion, fermentation and enzymatic digestion Lf generates bioactive 
peptides which can exhibit different properties respect native Lf. 
In 1992 it has been identified a region, called lactoferricin B (LFc B), that 
shows a greater antimicrobial activity than the full molecule. Subsequently 
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(Rodríguez-Franco et al., 2005) was observed that region corresponding to 
LFc B in bovine (residues 17-41) corresponds to residues 12-48 in other 
mammalian species with highly homologous sequences. Of course during the 
hydrolysis of bLf many peptides are generated, characterizing them it was 
found that minimal variations in amino acid sequence have effect on 
antimicrobial activity of peptide. For example LFampin 268-284 and LFampin 
265-284 that differs in only three amino acids presented different 
antimicrobial activity (van der Kraan et al., 2006). 
The bactericidal action of Lf is mediated by its lactoferricin (Lfcin) domain. 
Several studies have demonstrated that Lfcin is critical also for many binding 
properties to cell-surface molecules such as glycosaminoglycans, to bacterial 
surface molecules and LPS (Senkovich et al., 2007; Valenti and Antonini, 
2005; Puddu et al., 2010). 
 
5.1.8 In vitro evaluation of Lf protective role against cytotoxic stimuli 
Lf is an innate factor of the mammalian immune system; in particular in the 
bovine mammary gland bLf concentration dramatically increases in response 
to infection. Several studies have been conducted in order to evaluate the 
contribution of mammary epithelial cells in secreting immunological 
components after exposure to endotoxins using primary bovine mammary cell 
culture systems (Okada et al., 1997; Wellnitz and Kerr, 2004), the bovine 
mammary epithelial cell line MAC-T (Boudjellab et al., 1998), the murine 
mammary epithelial cell line HC11 (Zheng et al., 2006; Li et al., 2009) and 
bovine mammary explants (Rabot et al., 2007a). 
The established bovine mammary epithelial cell line BME-UV1 is an in vitro 
model of the bovine mammary epithelium that is able to synthesize α-
lactoalbumin and αs1-casein as well as express the components of the 
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plasmin-plasminogen system, that play a pivotal role in mammary gland 
development and defense mechanisms (Baldi et al., 1996; Politis, 1996; Cheli 
et al., 1999, Cheli et al., 2003). 
As describe above Lf could contribute to neutralize the effect of endotoxins 
through binding to their lipid A portion (Appelmelk et al, 1994; Baker and 
Baker, 2005).  
 
5.2 Aim  
With regard to this part of my PhD concerning Lf study, the aim was to 
evaluate the protective role of bLf, added to the culture medium, against a 
cytotoxicity stimuli identified in LPS. Furthermore I assessed if BME-UV1 
cells are able to express endogenous bLf after in vitro exposure to LPS. 
 
5.3 Materials and methods 
5.3.1 Cell line and cell culture 
The BME-UV1 cell line was created at the University of Vermont from 
primary bovine mammary epithelial cells in culture by stable transfection with 
SV-40 large T-antigen (Zavizion et al., 1996b) and is maintained in the 
Laboratory of Cell Culture – Department VSA (University of Milan; Italy). 
Cells are routinely cultivated into 75 cm2 tissue culture flasks (Costar, 
Corning, NY, USA), in a mixture of 50% DMEM-F12, 30% RPMI-1640 and 
20% NCTC-135 (Sigma-Aldrich, St. Louis, MO, USA), supplemented with 
10% fetal bovine serum (FBS) (BioWhittaker, Cambrex, Belgium), 0.1% 
lactose, 0.1% lactalbumin hydrolysate, 1.2 mM glutathione, 1 μg/ml insulin, 5 
μg/ml transferrin, 1 μg/ml hydrocortisone, 0.5 μg/ml progesterone, 10 μg/ml 
L-ascorbic acid and antibiotics (penicillin 100 IU/ml; streptomycin 100 
μg/ml). All medium supplements are from Sigma-Aldrich. 
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The cells are maintained at 37°C in a humidified 5% CO2 incubator until 
confluence. Cells used in the present work were at passage numbers between 
37 and 40.  
 
5.3.2 Determination of Inhibitory Concentration 50 of LPS  
Cell viability after incubation with LPS was determined by measuring the 
production of the chromophore formazan from 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide (MTT) (Sigma-Aldrich), as previously 
described (Baldi et al., 2004). Formazan is produced in viable cells by the 
mitochondrial enzyme succinate dehydrogenase. 
At confluence cells were detached from the flasks by trypsinisation (Trypsin-
EDTA 0.05%, Sigma-Aldrich) and re-suspended in complete culture medium 
to a concentration of 1.5×105 cells/ml. Then, cells were dispensed into wells 
of a 96-well tissue culture plate. After 24 h of incubation at 37°C in an 
atmosphere of 5% CO2, medium was removed and cell monolayer was 
washed three times with Hanks’ Balanced Salt solution (HBSS, Sigma-
Aldrich). BMEUV1 cells were then exposed to increasing concentrations of 
E. coli LPS O111:B4 (0-0.75- 1.5-3.12-6.25-12.5-25-50-100 μg/ml) (Sigma-
Aldrich) in DME-F12 medium without FBS. 
Cells incubated with DME-F12 medium alone, representing 100% viability, 
were included as negative controls. After 24 h media were removed, 150 μl 
MTT stock solution (5 mg/ ml) in PBS were added to each well and the plates 
were incubated for 3 h at 37°C in a humidified chamber. The reaction was 
terminated by removing the incubation solution and adding 150 μl dimethyl 
sulfoxide to dissolve the formazan. The optical density of the dimethyl 
sulfoxide solution at 540 nm was determined on a Biorad 680 micro plate 
reader (Biorad, Hercules, CA, USA). The percentage cytotoxicity was 
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calculated as follows: Percentage cytotoxicity = 1 x (mean optical density in 
presence of LPS / mean optical density of negative control) x 100. 
From these data the Inhibitory Concentration 50 (IC50) of LPS was calculated. 
At least three replicates were performed and the experiment was performed at 
least twice.  
 
5.3.3 Evaluation of the protective effect of bLf against LPS cytotoxicity  
In order to examine the protective role of bLf against LPS cytotoxicity, BME-
UV1 cells were re-suspended in complete culture medium to a concentration 
of 1.5×105 cells/ml and dispensed into wells of a 96-well tissue culture plate. 
After 24 h of incubation at 37°C in an atmosphere of 5% CO2, medium was 
removed and cells were washed three times with HBSS. They were 
subsequently treated with DMEM-F12 medium containing 30 and 50 μg/ ml 
of LPS O111:B4 in the presence or absence of various concentrations of bLF 
(6.25-12.5- 25-50 μg/ml). bLf was from bovine milk and was purchased from 
Sigma-Aldrich. LPS doses were selected according to the IC50, while bLf 
concentrations were chosen according to previous experiments (Pecorini et 
al., 2006). Negative control consisted of DMEM-F12 alone. After 24 h of 
treatment, the inhibition of LPS cytotoxicity by bLf was assessed by MTT 
test, as described earlier. The experiment included at least three replicates per 
treatment and was repeated at least twice. 
 
5.3.4 Isolation of total RNA after LPS exposure and evaluation of its quality  
The isolation of total RNA from BME-UV1 cells after LPS treatments was 
performed after assessing the effect on BME-UV1 viability of sub toxic levels 
of endotoxins, selected according to the cytotoxicity test carried out 
previously. Cells were seeded at the concentration of 1.5×105 cells/ml into 
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wells of a 96-well tissue culture plastic plate in complete culture medium 
containing 10% FBS. After 24 h, media were removed and cells were washed 
three times with HBSS. They were then treated with DME-F12 medium 
containing sub toxic concentrations (1-10-20 μg/ml) of LPS O111:B4. Cells 
incubated with DME-F12 medium alone, representing 100% viability, were 
included as negative controls. 
After 3, 6, 12 and 24 h of incubation in the presence of LPS, cell viability was 
assessed by MTT test, as described earlier. There were at least three replicates 
per treatment and the experiment was repeated at least twice. In order to 
isolate total RNA, BME-UV1 cells were seeded in 60-mm Petri dishes at the 
concentration of 0.2–0.4×106 cells/ml in complete medium containing 10% 
FBS. 
After 24 h, media were removed, cells were washed three times with HBSS 
and complete medium containing 1, 10 or 20 μg/ml of LPS was added. 
Control consisted in complete medium with omission of LPS. After 3, 6, 12 
and 24 h, total RNA was extracted by TRI Reagent (Sigma-Aldrich) following 
manufacturers’ instructions and stored at −80°C. 
The quality and the integrity of total RNA samples from LPS treated and 
control BMEUV1 cells were confirmed by the following approaches. Firstly, 
the optical density OD260 nm/OD280 nm absorption ratio was measured by 
a NanoDrop ND-1000 UV-Vis Spectrophotometer. Secondly, RNA samples 
were separated on 1.6% agarose gel containing formaldehyde and stained with 
etidium bromide. The presence of intact 28S and 18S rRNAs was checked 
under ultraviolet light. Finally, cDNA of β-actin was detected by reverse 
transcription-polymerase chain reaction (RT-PCR). First-strand cDNA was 
synthesized by reverse transcription with M-MuLV Reverse Transcriptase 
(Fermentas, Burlington, Canada) and random nonamers primers (Sigma-
Aldrich) at 37°C for 60 min. 
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Negative controls were prepared under the same conditions without reverse 
transcriptase. cDNA (1/10 of reverse mixture) of β-actin was amplified by 
using the forward primer ACT-for and the reverse primer ACT-rev (Table 2). 
Amplification reactions were performed in Gene Amp PCR System 9700 
(Perkin Elmer, Waltham, MA, USA) with the enzyme AccuTaq LA DNA 
Polymerase (Sigma-Aldrich) by initial denaturation at 96°C for 30 s, followed 
by 30 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 30 s, 
extension at 68°C for 30 s and final extension at 68°C for 10 min. PCR 
products were separated on 2% agarose gel in 1% TBE buffer and stained 
with etidium bromide. Their expected size was 178 bp.  
 
Gene GenBank Accession 
Number 
Primer 
name 
Primer sequence (5’→3’) Product 
length 
β-actin NM_173979 ACT-for ATCGTCCGTGACATCAAGGAG 178 bp 
  ACT-rev CTCTTCCAGCCTTCCTTCCT  
bLf L08604 bLf-for 1* GGCCTTTGCCTTGGAATGTATC 338 bp 
  bLf-rev 1* ATTTAGCCACAGCTCCCTGGAG  
  bLf-for 2 CCACCAGCAGGCTCTGTTTG 132 bp 
  bLf-rev 2 CGTTGGTCTGCCTCCAAGT  
  bLf-for 3 CGACAGTGTTTGAGAACTTGCC 131 bp 
  bLf-rev 3 GACAGCATGAGAAGGGACCTG  
* The sequence of these primers was from Pfaffl et al. (2003) 
 
Table 2: Sequences of PCR primers for β-actin and bLf. Primer names, GenBank Accession number of the used 
published bovine nucleic acid sequences and products length are indicated 
 
5.3.5 Evaluation of bLf mRNA expression by Real-Time PCR 
In order to evaluate whether BME-UV1 cells are able to express endogenous 
bLf after in vitro exposure to the different LPS treatments, a Sybr Green Real-
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Time PCR approach was used. First-strand cDNA was synthesized by reverse 
transcription with M-MuLV Reverse Transcriptase (Fermentas) and random 
nonamers primers (Sigma-Aldrich) at 37°C for 60 min. Three primer pairs for 
the amplification of a fragment of the bLf cDNA were tested (Table 2). The 
primer pair bLf-for1 and bLf-rev1 was designed by Pfaffl et al (2003), while 
the other two bLf primer pairs were designed for this study using Primer3 v 
0.4.0 (Rozen and Skaletsky, 2000). β-actin was chosen as the housekeeping 
gene (Fusi et al., 2002) and the primer pair ACT-for, ACT-rev was used 
(Table 2). All Real-Time PCR reactions were performed on Biorad IQ5 
(Biorad) using 400 nm of each primer, 12.5 μl of BIORAD IQ Sybr-Green 
Supermix (Biorad) and various cDNA quantities were tested, ranging from 25 
ng to 1 μg. 25 ng of cDNA obtained from bovine mammary gland tissue was 
included as a positive control in all reactions. The thermal profile used for all 
experiments was as follows: 95°C for 2 min, 40 cycles of 95°C for 30 s, 60°C 
for 30 s and 72°C for 30 s, with a final melt curve from 55°C to 95°C with 
increment of 0.5°C per cycle. 
 
5.4 Statistical analysis 
Results are presented as mean and SD. Effects of various treatments were 
evaluated by oneway analysis of variance using the GLM procedure of SAS 
(version 9.1, SAS Institute Inc., Cary, NC, USA). Mean comparisons were 
done using Duncan’s multiple range test with P<0.05 as the level of 
significance.  
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5.5 Results 
5.5.1 Protective role of bLf against LPS cytotoxicity  
The cytotoxicity of LPS on BME-UV1 cell line was evaluated by MTT test. 
After 24 h, the IC50 was 47.44 μg/ml. According to the IC50, BME-UV1 cells 
were treated for 24 h with two concentrations of LPS, 30 and 50 μg/ml, in 
order to examine the protective effect of exogenous bLf against endotoxins 
cytotoxicity. In the presence of 30 μg/ml of LPS, bLf treatments did not limit 
significantly endotoxins cytotoxicity, whereas in the presence of 50 μg/ml of 
LPS, bLf contributed to reduce significantly (P<0.05) LPS cytotoxicity (Fig. 
14). 
 
 
Fig. 14: Evaluation of the protective effect of exogenous bLf against LPS cytotoxicity. BME-UV1 cells have been 
treated with both LPS and bLf for 24 h, and the defensive role of bLf has been evaluated by MTT test.  
*P:<0.05 
 
5.5.2 Investigation of bLf mRNA expression after LPS exposure  
The effect of sub toxic concentrations of LPS, chosen according to the 
cytotoxicity test, was evaluated by MTT test. As shown in Fig. 15, sub toxic 
levels of LPS did not evidenced cytotoxic effects on BME-UV1 cells. 
* 
* 
* 
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Fig. 15: Effect of sub toxic levels of LPS on the viability of BME-UV1 cells. Cells have been treated with sub toxic 
concentrations of LPS, as described in the Materials and Methods section, for 3, 6, 12 and 24 h. The effect of the 
treatments on cell viability has been evaluated by MTT test 
 
The total RNA samples extracted from BME-UV1 cells after LPS treatments 
revealed optical density OD260nm/OD280nm absorption ratios comprised 
between 1.98 and 2.00, thus documenting the good quality of the nucleic acid. 
The total RNA integrity was confirmed by the presence of intact 28S and 18S 
rRNAs under ultraviolet light after denaturated agarose gel (Fig. 16a). 
Moreover, the expected band of 178 bp, corresponding to the β-actin, was 
detected in all samples, whereas no amplification product was found in 
control samples without reverse transcriptase, thus confirming the quality and 
the integrity of the total RNA extracted (Fig. 16b). Real-Time PCR on bLf 
was performed on all cDNA samples, testing different cDNA quantities, and 
did not show any amplification of bLf in any of the cDNA examined, neither 
from LPS treated cells nor from control cells. Successful amplification of bLf 
from mammary gland tissue cDNA (data not shown) indicates the 
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effectiveness of the three primer pairs used, while successful amplification of 
β-actin from cell line cDNAs confirms the quality of the templates. 
 
 
Fig. 16: Representative image of the integrity and quality of total RNA extracted from BME-UV1 cells after 24 h of 
LPS treatments by denaturing gel electrophoresis (a) and β-actin amplification (b). The amplification of β-actin 
produced a band of 178 bp (arrow), whereas no amplification product was found in control samples without reverse 
transcriptase (N). 0, 1, 10 and 20 refer to the LPS treatments. M=50 bp DNA ladder 
 
5.6 Discussion 
The present work has shown that exogenous bLf has a protective effect 
against LPS cytotoxicity in the BME-UV1 in vitro model. Depending on the 
dose, LPS not only are toxic to a number of target cells, but also significantly 
alter normal cell functions (Buommino et al., 1999). Since cells were incubated 
in presence of both bLf and LPS, the defensive role of bLf could be related to 
its cationic nature, which allows the neutralization of LPS by binding to their 
anionic lipid A portion (Appelmelk et al., 1994; Puddu et al., 2010). Several 
studies have documented the protective effect of Lf against endotoxin 
mediated damage. Hirotani et al. (2008) have reported the defensive role of Lf 
against LPS mediated intestinal mucosal damage in human intestinal epithelial 
Caco-2 cell line and in vivo studies have provided evidence that orally 
administered bLf has a beneficial effect against a lethal dose of LPS, thus 
preventing septic shock (Lee et al., 1998; Kruzel et al., 2000). Tian et al. (2010) 
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have reported the cytoprotective effect of bLf against endotoxin LPS in both 
immune cells and colon epithelial cells. bLf is also a protective factor against 
LPS-induced diarrhea in mice, by modulating the cyclooxygenase pathway in 
the gut (Talukder and Harada, 2007). In the mammary gland LPS 
neutralisation by Lf may contribute to counteracting tissue damages induced 
by oxidative stress at the sites of inflammation during mastitis (Nuijens et al., 
1996). In support to this, accumulating evidence has pointed out to a role for 
Lf as a potent antioxidant molecule. Lf is involved in the inhibition of reactive 
oxygen species production mediated by the binding of LPS to L-selectin on 
neutrophils (Baveye et al., 2000). In addition, the protein serves as a scavenger 
of free iron, which accumulates in inflamed tissues and provokes the release 
of hydroxyl radicals (Legrand et al., 2006). It has been reported that in 
neurodegenerative diseases, in which iron accumulation leads to oxidative 
stress and neuronal death, Lf is overexpressed in specific areas of the brain, 
thus supporting the role of Lf as a protective factor against oxidative damage 
(Fillebeen et al., 2001). In addition, Kruzel et al. (2009) have shown that Lf 
attenuates oxidative insult at the mitochondrial level after LPS exposure. In 
the present work we have also examined whether BME-UV1 cells are able to 
express endogenous bLf mRNA after LPS exposure. In vivo, it has been shown 
that injection of bovine mammary gland with E. coli LPS caused a significant 
increase within hours of bLf mRNA expression (Pfaffl et al., 2003; Schmitz et 
al., 2004). In addition, a rise in bLf mRNA expression after LPS challenge has 
been observed in a primary bovine mammary cell culture system (Wellnitz and 
Kerr, 2004) and the murine mammary epithelial cell line HC11 (Li et al., 
2009). However, in BME-UV1 cells Real-Time PCR analysis carried out on 
total RNA from control and LPS treated cells did not allow the detection of 
bLf mRNA expression, whereas Lf mRNA expression was detected in the 
positive control from bovine mammary gland tissue (data not shown). On one 
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hand, the discrepancy in terms of bLf mRNA expression observed between 
BME-UV1 and other in vitro models of the bovine mammary epithelium used 
in previous studies could be explained by the lack of LPS responsive elements 
in BME-UV1 cell line and are in line with outcomes of others. Zheng et al. 
(2005) have provided evidence that Lf promoter contains LPS-responsive 
regions and that the response to infection is mediated by the NF-kappaB 
pathway. It is tempting to consider that inBME-UV1 cells these regions are 
not functional. On the other hand, the fact that bLf mRNA expression has 
not been detected in BME-UV1 cells could be explained by the lack of Lf 
expression observed in immortalized mammary cell lines (Panella et al., 1991). 
In support of this, the bovine mammary epithelial cell line MAC-T cells do 
not appear to produce Lf (Zheng et al., 2005). Interestingly, Baumrucker et al. 
(2003) have found that BME-UV cells show faint expression of bLf after 
treatment with retinoic acid. In conclusion, our results showed that in BME-
UV1 cells exogenous bLf acts as a protective factor against LPS cytotoxicity, 
while the response to LPS treatments does not involve endogenous bLf 
mRNA expression. 
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6. Plasmin-plasminogen system in bovine 
mammary gland 
 
6.1 Introduction 
The plasmin-plasmnogen system plays a crucial role in a variety of 
extracellular proteolytic events, such as fibrinolysis, cell migration and tissue 
remodelling events (Schaller and Gerber, 2010). The cascade of reactions that 
leads to plasminogen activation is controlled by a complex network of 
molecular interactions between plasminogen activators (urokinase-type, u-PA 
and tissue-type, t-PA) and at least two types of plasminogen activator 
inhibitors (PAI-1 and PAI-2) (Lampidonis et al., 2011). The inactive 
plasminogen is present in most body fluids, including milk, and it can be 
defined as a “proteolytic reservoir” due to its unlimited supply of proteolytic 
activity (Politis, 1996). During tissue remodeling events, plasmin plays its role 
by acting on proteins located both at the extracellular matrix and basement 
membrane level of cell leading to its proteolysis and, consequently, 
detachment from the basal lamina. 
At the same time, plasmin initiates a cascade of reactions that cause the 
activation of other degradative enzymes called matrix metalloproteinases 
(MMP) (Deryugina and Quigley, 2012).  
MMPs are a family of extracellular soluble or membrane-bound proteases that 
can degrade or modify all major components of the matrix including 
extracellular collagen, laminin and proteoglycans (Cuadrado et al., 2008). As 
described in literature, the involvement of plasmin-plasminogen system in 
invasive and metastatic tumors, in the invasiveness and metastatic potential of 
cancer seems to be correlated with the activity of u-PA localized on the cell 
membrane. As a consequence the system plays a crucial role in leading local 
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destruction of the extracellular matrix and it is involved in cancerous cells 
migration and metastases generation. The role of u-PA in development of 
malignant tumours has been studied and highlighted in different types of 
cancers including breast and liver cancers (Tang and Han, 2012). 
A prime example of tissue that undergoes extensive tissue remodelling 
throughout its growth and its development is the mammary gland (Theodorou 
et al., 2010). In ruminants, after weaning or following cessation of milking, 
major well-controlled degenerative events occur as the mammary gland is 
remodelled in preparation for the next lactation (Lampidonis et al., 2011). 
There is evidence proving its role in mammary gland both in physiological and 
pathological conditions, such as during mastitis. 
 
6.1.1. Plasminogen and plasmin in bovine milk 
Bovine plasminogen is a single-chain glycoprotein of 786 amino acids that 
consists of five characteristic loop structures called kringles that are 
responsible for binding between plasminogen and fibrin in blood system and 
casein in milk. Plasminogen is converted in the active and proteolytic form, 
called plasmin, by the action of plasminogen activators (PAs), which are able 
to cleave plasminogen at the Arg 557-Ile558 peptide bond [L. Berglund, M.D. 
Andersen, and T.E. Petersen, 1995, unpublished data ](Schaller et al., 1985). 
Plasmin, formed by this process, is a serin protease able to degrading some 
matrix components and activates other matrix-degrading enzymes (Silanikove 
et al., 2006). 
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Fig 17: Three dimentional structure of plasmin . 
(http:// upload.wikimedia.org/wikipedia/it/thumb/6/6d/Plasmina.png/199px-Plasmina.png) 
 
The resulting activated plasmin (Fig.17) consists of two chain held together by 
disulfide bonds. It is involved in a wide variety of biological function ranging 
from thrombolysis to tissue remodeling (Alfano et al., 2005). This serine 
protease is a heat-stable enzyme and its optimal pH is of 7.4. Plasmin shows a 
trypsin-like specificity cleaving peptide bonds adjacent to Lys or Arg. In milk 
both αs- and β-casein are hydrolyzed by plasmin, which, however, does not 
seem to be able to act on κ-casein (Politis, 1996). 
 
6.1.2. Plasminogen activators and Plasminogen activator inhibitors 
In mammals exists two types of PA enzymes: urokinase-PA (u-PA) and tissue-
PA (t-PA). Although both of these two enzymes cleave the same peptide 
bond of their substrate, plasminogen, they are antigenically distinct and 
derived from different genes. 
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Bovine u-PA is a single-chain consisting of 413 amino acids, it can be 
converted in two chain u-PA held together by disulfide bonds, this form is 
enzymatically more active than single-chain (Politis, 1996).  
u-PA is composed of (Politis, 1996):  
• Epidermal growth factor (EGF)-like domain that is structurally similar 
to the receptor-binding region of EGF; 
• One kringle structure 
• Carboxyl terminal region that contains the active site of the enzyme. 
EGF-like domain and kringle structure form the amino-terminal fragment 
(ATF) that mediates binding between u-PA and specific cellular receptor 
presents on numerous cell types. 
t-PA is composed of (Danø et al., 1985; Saksela and Rifkin, 1988): 
• EGF-like domain 
• Two kringles structures 
• Carboxyl terminal region 
• Finger-like domain that is highly homologous with the fibrin-binding 
fingers present in fibronectin. 
Conversely to u-PA, t-PA has high affinity for fibrin. High affinity is due to 
the presence, in t-PA structure, of the finger domain and the two kringles 
structure. When t-PA binds fibrin occurs a conformational change that 
decreases the Michaelis constant of t-PA for plasminogen enhancing the 
enzyme activity, but this not occurs when fibrin binds u-PA (Zamarron et al., 
1984). The different response of this binding with fibrin is the bases for the 
general belief that the physiological function of t-PA is in thrombolysis while 
that of u-PA is in tissue remodeling events (Danø et al., 1985; Saksela and 
Rifkin, 1988). 
The interaction between PAs activity and its specific inhibitors (PAIs) 
controls the rate of plasminogen conversion (Fig.18). Two fast-acting PAIs 
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have been identified and designated PAI-1 and PAI-2; while the third 
inhibitor, PAI-3, isolated from urine, shows an inactivating ability slower than 
other two PAIs (Andreasen et al., 1990; Danø et al., 1985; Saksela and Rifkin, 
1988). 
 
 
Fig 18: PAI-1 action ( Brown NJet al., 2000) 
 
The rapidity of interaction between inhibitors and activators is an important 
parameter to evaluate the efficacy inhibitors so PAI-1 and PAI-2 inactivate 
rapidly PA forming equimolar complexes with u-PA and t-PA. In addition to 
PA inhibitors, there are inhibitors that act directly on plasmin; the two most 
important of which are α2-antiplasmin and α2-macroglobulin. The last one is 
a nonspecific inhibitor that reacts with the most of proteases while α2-
antiplasmin is a specific and rapidly plasmin inhibitor (Politis, 1996). 
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6.1.3. u-PA receptor  
u-PA receptor (u-PAR) is a membrane protein able to bind u-PA with high 
affinity (dissociation constant= 0.1 to 1 mmol/l) (Politis, 1996). 
Bovine u-PAR is a protein of 310 amino acids highly glycosylated with six N-
linked glycosylation sites (Kratzschmar et al., 1993; Reuning et al., 1993). u-
PAR is composed of three structurally homologous domains each of which is 
characterized by a high cysteine content (9%).  
 
 
Fig.19: uPAR structure (http://www.nature.com/emboj/journal/v24/n9/fig_tab/7600635f6.html) 
 
The amino acid sequence of each repeat is distantly related with a homology 
lower than 20%. u-PAR is attached to cell surface by an anchor of glycosyl, 
phophatidyl and inositol (GPI) (Fig.19) whose biological significance may lie 
in the greater lateral mobility than other transmembrane proteins (Politis, 
1996). At NH2 terminal region level of u-PAR there is the repeat appointed to 
bind the EGF-like domain, which is part of ATF region of u-PA (Saksela and 
Rifkin, 1988).  
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The primary function of u-PAR is to localize plasminogen activation at the 
cell surface because u-PA bound to its receptor retains its proteolytic activity 
(Fig.20) (Theodorou et al., 2011).  
 
 
 
Fig 20: uPA-uPAR system ( Blasi&Carmeliet,2002) 
 
Bound between u-PA and u-PAR, leading to accelerate production of plasmin 
and initiates a cascade of reactions determining degradation of extracellular 
matrix proteins during tissue remodeling events (Politis, 1996). Plasmin so 
formed owns different behaviour from that in solution; in fact, α2-antiplasmin 
inactivates plasmin on the membrane more slowly than that in solution (Ellis 
and Dano, 1991; Ploug et al., 1991). On the contrary, PAI-1 is able to inhibit 
both types of plasmin. When u-PA is bound to u-PAR, forming a complex 
with PAI-1 is internalized by the cell. This complex is degraded into the cell 
and u-PAR is recycled on the cell membrane (Ellis and Dano, 1991; Nguyen 
et al., 1992; Nusrat and Chapman Jr, 1991); thus bound between PAI-1 and 
receptor-bound u-PA provides a mechanism that continuously change the 
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proteolytic activity on cell surface (Politis, 1996). Without this binding, 
receptor-bound u-PA would be equally internalized but more slowly than the 
complex (Ellis and Dano, 1991; Nguyen et al., 1992; Nusrat and Chapman Jr, 
1991). 
 
6.1.4 Role of plasmin-plasminogen in cell growth 
Already in the early 1990s was known a correlation between cell proliferation 
and expression of u-PA. Politis (1996) has shown that the most powerful 
growth regulators of cultured cells are among the main factors regulating u-
PA expression in vitro. Comparing several studies, Alfano et al. (2005) have 
concluded that u-PA may support cell proliferation and the matrix remodeling 
associated with tissue regeneration by plasmin-mediated activation of other 
proteinase classes and growth factors as well as through u-PAR-dependent 
signaling. 
Despite, at the molecular level, u-PA and PAI-1 have been extensively 
analyzed in human and rodents, there is limited evidence regarding the role of 
genes implicated in the plasmin-plasminogen system in the bovine mammary 
gland.  
Politis et al. (1989) have shown that the conversion of plasminogen to plasmin 
is related to the gradual decline faced by the gland breast. Baldi et al. (2002) 
have observed that during late lactation both plasmin and PAs increase and 
the rate between plasminogen and plasmin decreases indicating an increase in 
the conversion of plasminogen to plasmin during this phase. Rabot et al 
(2007b) have detected that, in dairy cow, during late lactation, u-PA, u-PAR 
and PAI-1 expression increased suggesting that high levels of expression of 
these enzymes might be considered a characteristic of the non-lactating gland. 
In contrast with what is known in other species, in the same study, were also 
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observed high levels of expression of all three genes in mammary tissue 
obtained from lactating dairy cows. 
With respect to cell growth, the evidence regarding the role of u-PA/u-
PAR/PAIs is limited and conflicting as well. Politis et al. (1995) have revealed 
that PA synthesis is controlled by lactogenic hormones and growth factors 
and is, also, influenced by extracellular support on which epithelial cells are 
cultured. In the same study, it has been reported that in MAC-T cell line, 
treated with insulin and insulin growth factor-1 (IGF-1), there had been an 
enhanced cell proliferation accompanied by increased both u-PA gene 
expression and u-PA activity. 
Cheli et al (2003), conversely, have showed that retinoids treatments were able 
to inhibit BME-UV1 cell proliferation but not u-PA gene expression or 
activity. 
 
6.1.5 Correlation between plasminogen-plasmin system and pathological 
conditions 
Plasminogen-plasmin system can be activated not only by physiological stimuli 
but also in pathological conditions such as during the course of mastitis. 
Mastitis is an inflammation of the mammary gland and represents the most 
costly disease in the dairy industry (Zhao and Lacasse, 2008). The main cause 
of mastitis is intramammary bacterial infection, generally due to the gram-
negative bacteria. Among them, Escherichia coli cause mainly acute and severe 
infections in high-producing cows, in particular around parturition or during 
early lactation (Burvenich et al., 2003; Hogan and Larry Smith, 2003). 
During clinical and subclinical infections of the mammary gland, has been 
observed an increase both in proteolytic activity in milk and in plasmin 
plasminogen activator and in somatic cell count (Baldi et al., 1996; Politis et 
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al., 2004). In neutrophils and monocytes of dairy ewes has been observed an 
up-regulation of expression of u-PA, u-PAR and PAI during mastitis 
(Theodorou et al., 2010). Furthermore, Long et al. (2001) have detected, in 
bovine mammary tissue during E.coli-induced mastitis, an increased expression 
of u-PA mRNA. 
Important components of E. coli and other gram negative bacterial wall, 
namely LPS, are able to induce a significant increase within hours in mRNA 
expression and release of inflammatory mediators and protective factors, such 
as cytokines and antimicrobial proteins (reviewed in Rainard and Riollet, 
2006). Several surveys (Ohta et al., 2000; Long et al., 2001; Cunningham et al., 
2009) have shown that LPS can upregulate the expression of the component 
of the plasmin-plasminogen system in several tissues, such as the microglia 
and human prostatic cancer cells. Even though we know that LPS is able to 
stimulate plasmin-plasminogen system and that E. coli is the most common 
aethiological agent causing acute and severe intrammary infection. 
Investigations in this direction can contribute to provide more insights into 
the correlation between mammary gland defense mechanisms against the most 
common agents isolated from acute cases of mastitis. 
 
6.2 Aim 
This section of my work is divided in two studies, in the first of these, the aim 
was to determine the effect of growth factors (IGF-1 and EGF-1) and three 
hormones (insulin, dexamethasone and prolactine) on expression of 
plasminogen activator (PA)-related genes (u-PA, u-PAR, PAI-1 and PAI-2) 
and BME-UV1 cell proliferation. I used BME-UV1 cell line that represents an 
in vitro model of bovine mammary epithelia and, at the same time, is able to 
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produce itself the components of the plasminogen activator system (Cheli et 
al., 1999). 
In the second study the aim was to investigate the effects of E. coli LPS, used 
in order to simulate E. coli infection of the mammary epithelium in vitro, on 
cell viability, modulation of cell-associated u-PA activity and the regulation of 
u-PA and u-PAR RNA expression on mammary gland I used BME-UV1 cells. 
 
1st study 
 
6.3 Material and methods  
6.3.1 Cell culture 
The BME-UV1 cell line was established from primary bovine mammary 
epithelial cells by stable transfection with a plasmid, carrying the sequence of 
the simian virus 40 early region mutant tsA58, encoding the thermolabile large 
T antigen (Zavizion et al. 1996b) and is maintained in the Laboratory of Cell 
Culture, Department of Veterinary Science and Technologies for Food Safety 
of University of Milan. Cells are routinely cultivated into 75-cm2 tissue culture 
flasks (Corning Life Sciences, Corning NY, USA), in normal growth medium 
which consisted of 50% DMEMF12, 30% RPMI-1640 and 20% NCTC-135 
(Sigma-Aldrich, St. Louis MO, USA), supplemented with 10% fetal bovine 
serum (FBS) (Lonza, Basel, Switzerland), 0.1% lactose, 0.1% lactalbumin 
hydrolysate, 1.2 mM-glutathione, 1 μg/ml insulin, 5 μg/ml transferrin, 1 
μg/ml hydrocortisone, 0.5 μg/ml progesterone, 10 μg/ml L-ascorbic acid and 
antibiotics (penicillin 100 IU/ml; streptomycin 100 μg/ml). All medium 
supplements are from Sigma-Aldrich. Cells are maintained at 37 °C in a 
humidified 5%-CO2 incubator until confluence. 
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6.3.2 Cell proliferation 
The first experiment examined the effect of the various hormonal and growth 
factor treatments on cell proliferation using two methodologies. The first 
method included the use of the MTT assay, which measures the production of 
the chromophore formazan from 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) in cultured cells (Sigma-Aldrich), as 
previously described (Baldi et al., 2004). Formazan is produced in viable cells 
by the mitochondrial enzyme succinate dehydrogenase. The second 
methodology used was direct cell enumeration. All details of this method have 
been described by Politis et al. (1995). Results paralleled those of the MTT 
assay and therefore are not presented in detail in the Results section. Cells 
were seeded (2.5×104 cells) in each well of 96-well tissue culture plastic plates 
(Corning Life Sciences) in normal growth medium. After 24 h media was 
removed, cells were washed twice with Hank’s balanced salt solution (HBSS) 
and test medium was added. Test medium consisted of serum-free DMEM 
alone, used as control, and serum-free DMEM containing insulin (bovine; 0·1 
and 1 μg/ml), EGF (human; 50 ng/ml), IGF-1 (mouse; 50 ng/ml), prolactin 
(ovine; 0.01 and 1 μg/ml), dexamethasone (100 nM), dexamethasone (100 
nM) plus insulin (1 μg/ml) and dexamethasone (100 nM) plus prolactin (1 
μg/ml). All hormones and growth factors were purchased from Sigma-
Aldrich. Preliminary time-course experiments showed that both IGF-1 and 
EGF affected cell proliferation at 24, 36 and 48 h but not at 12 h of 
incubation. Therefore, incubation for 24 h was selected in all subsequent 
experiments. Furthermore, other preliminary experiments with various doses 
of the growth factors were performed to detect the optimum concentrations 
of IGF-1 and EGF. With respect to IGF-1, three concentrations were tested 
(1, 10 or 50 ng/ml) and the optimal concentration was found to be the 50 
ng/ml which is consistent with the concentration used by Zavizion et al. 
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(1996b) in the BME-UV cells. With respect to EGF, two concentrations were 
tested (10 or 50 ng/ml) and they were equally effective but the concentration 
of 50 ng/ml gave more consistent results. This concentration is higher than 
the 10 ng/ml utilized by Zavizion et al. (1996b) and Accornero et al. (2009) in 
the BME-UV cells. The concentrations of all three hormones (insulin, 
dexamethasone and prolactin) were similar to those utilized by Politis et al. 
(1995) in the MAC-T cell line which was derived in a similar manner with 
BME-UV cell line. After 24 h of incubation, treatment test medium was 
removed, then 150 μl MTT stock solution (5 mg/ml) in PBS was added to 
each well and finally the plates were incubated for 3 h at 37 °C in a humidified 
chamber. The reaction was terminated by removing the incubation solution 
and adding 150 μl of dimethyl sulphoxide to dissolve the formazan. The 
optical density of the dimethyl sulphoxide solution at 540 nm was determined 
on a Biorad 680 microplate reader (Biorad, USA). The percentage of cell 
proliferation was calculated as follows: Percentage cell proliferation=(mean 
optical density in presence of treatment/mean optical density of 
control)×100. For each treatment three biological replicates were used and the 
experiment was performed twice.  
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Target 
Gene 
Name Oligonucleotide sequences (5’→3’) Primer 
length 
Amplic
on size 
Corresponding GenBank 
sequence 
b-actin F_b-actin CCAAAGCCAACCGTGAGA 18 nt 114 bp AF481159.1(C.Hircu) 
 R_b-actin CCAGAGTCCATGACAATGC 19 nt  AY141970.1(B. aurus) 
u-PA F_u-PA GGCCAGAAGGCTCTGAGGC 19 nt 133 bp BT030737.1(B.Tauru) 
 R_u-PA GGCTGCCACCACACAAGTAGG 21 nt   
u-PAR F_u-PAR GGGACAGGACCTCTGCAGG 19 nt 117 bp NM_001005377.2(H. Sapiens) 
 R_u-PAR CGATAGCTCAGGGTCCTGTTG 21 nt  NM_174423.3(B.Taurus) 
     NM_011113.3 (M. Musculus) 
PAI-1 F_PAI-1 CTACACTGAGTTTACCACCC 20 nt 234 bp BT025406 (B. Taurus) 
 R_PAI-1 GACATTCCCAAGTTCTCCAG 20 nt   
PAI-2 F_PAI-2 CTTGGAGTTGCTGGAGAG 18 nt 229 bp NM_001192051.1 (B. Taurus) 
 R_PAI-2 ACACTTCAGACAGAAACAGG 20 nt   
 
Table 3. Nomenclature, nucleotide sequences, length of the primers used and the size of the resulting amplicons for 
all Real time PCR reactions 
 
6.3.3 Gene expression of PA-related genes  
The second experiment examined the effects of insulin, EGF, IGF-1, 
prolactin and dexamethasone (Sigma-Aldrich) on expression of four PA-
related genes. Cells were seeded in 6-cm culture dishes (106 cells) in normal 
growth medium. After 24 h media were removed, cells were washed twice 
with Hank’s balanced salt solution (HBSS) and test medium was added for 
another 24 h. Test medium used was the same as described in the first 
experiment. After 24 h of incubation, cells were removed by complete 
trypsinization and RNA was extracted using TRI reagent (Sigma-Aldrich). 
Relative levels of mRNA were quantified with real-time, quantitative RT-PCR. 
A pair of primers for each of the target genes (u-PA, u-PAR, PAI-1 and PAI-
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2) and the housekeeping gene (β-actin) was constructed using PERL primer 
software (Marshall, 2004). Primers for u-PA, PAI-1 and PAI-2 were designed 
based on Bos taurus sequences, while β-actin and u-PAR primers were 
designed in highly homologous regions, between different species, of their 
respective cDNAs. PCR products from all primer pairs used were verified by 
sequencing. All primer pairs are presented in Table 3. The amount of sample 
RNA was normalized by using β-actin as a housekeeping gene. Equal amounts 
of total RNA were reverse transcribed with the iScript™cDNA Synthesis Kit 
(Biorad, Hercules CA, USA) according to the manufacturer’s instructions 
using a mix of random hexamers and oligo-dT primers. Real time PCR was 
performed in the MyiQ2 cycler (BioRad) using the SsoFast™ EvaGreen® 
Supermix (BioRad) according to the manufacturer’s protocol. Each reaction 
(total volume 20 μl) for the quantification of the housekeeping gene and the 
target genes contained 50 ng RNA equivalents as well as 450 nM of forward 
and reverse primers for b-actin and PAI-1 and 350 nM of forward and reverse 
primers for u-PA, u-PAR and PAI-2. The reactions were incubated at 95 °C 
for 30 s followed by 40 cycles of 5 s at 95 °C and 10 s at 60 °C. This was 
followed by a melt curve analysis to determine the reaction specificity. For 
each treatment two biological replicates were used, each sample was measured 
in duplicate and the experiment was performed twice. The comparative Ct 
method was used for relative quantification. The amount of target normalized 
to b-actin and relative to a calibrator, is given by 2 -ΔΔCT.  
 
6.3.4 Determination of PA activity  
The third experiment examined the effect of the insulin, EGF, IGF-1, 
prolactin and dexamethasone on cell-associated, membrane-bound and 
secreted u-PA activity by BME-UV cells. Cells were seeded (1.5×105 cells) in 
90 
 
each well of 24-well tissue culture plastic plates (Corning Life Sciences) in 
normal growth medium. After 24 h media were removed, cells were washed 
twice with Hank’s balanced salt solution (HBSS) and test medium was added 
for another 24 h. Test medium used was the same as described in the first 
experiment. After hormonal treatment the medium was recovered and stored 
for the determination of secreted PA activity. The protocol used for recovery 
of cell-associated and membrane-bound PA has been described previously 
(Stoppelli et al., 1986). Briefly, membrane-bound u-PA, was recovered by a 3-
min treatment at room temperature with 50mM-glycine–HCl buffer, pH 3·0, 
containing 0·1 M-NaCl, then quickly neutralized with 0.5 M-Hepes buffer, pH 
7.5 containing 0.1 M NaCl. Cell-associated u-PA was obtained from cells after 
lysis with 1% Triton X-100, 20mM Hepes buffer, pH 7.5, containing 10% 
glycerol. PA activity in all three fractions was quantified using the method 
described by Politis et al. (1995) and Politis (1996). This method is based on 
the conversion of exogenously provided plasminogen to plasmin from the PA 
present in the fraction. Plasmin so produced, is subsequently allowed to attack 
the chromogenic substrate Valine-Leucine-Lysine-p-nitroaniline adjacent to 
Lysine and liberate the free chromophore p-nitroaniline (Sigma Aldrich). In 
this system, changes in colour are directly related to plasmin levels and 
therefore indirectly to PA activity. All forms of PA activity were normalized 
by the number of cells. Cell numbers were quantified using a haemocytometer 
after trypsinization. For each treatment three biological replicates were used, 
each sample was measured in triplicate and the experiment was performed 
twice. 
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6.4 Statistical analysis  
All data are presented as means and SEM. The effect of the various 
treatments was assessed by ANOVA. Fischer’s LSD test was used post hoc, 
with a 95% confidence interval. All analyses were performed using the PASW 
Statistics 18 release 18.01 (SPSS Inc., USA) program. 
 
6.5 Results  
The effect of growth factors and lactogenic hormones on cell proliferation 
following 24 h incubation was determined and the results are presented in Fig. 
21. Both IGF-1 and EGF caused significant increases in cell proliferation. 
However, EGF was a more effective (P<0.01) mitogen than IGF-1. No effect 
(P>0.05) was observed when cells were cultured in the presence of insulin, 
prolactin, dexamethasone. The combinations of dexamethasone with insulin 
or prolactin showed a trend for increased cell proliferation, but it was not 
significant.  
 
 
 
 
 
 
 
 
 
 
Fig. 21. Effect of lactogenic hormones [insulin (Ins), prolactin (PRL) and dexamethasone (DEX)] and growth factors 
(EGF and IGF-1) on cell proliferation of BME-UV1 mammary epithelial cells after 24-h treatment. Treatment 
combinations were made using the highest concentration for each compound. All data are presented as means±SEM 
(n=6). Means without a common letter differ *P: <0.05. 
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The effect of growth factors and lactogenic hormones on expression of u-PA 
and u-PAR, by bovine mammary epithelial cells was examined and the results 
are presented in Fig. 22. IGF-1 caused 2-fold increases (P<0.05) in expression 
of u-PA (Fig. 22A) and u-PAR (Fig. 22B). EGF caused a 3·8-fold increase 
(P<0.01) in expression of u-PAR (Fig. 22B).  
 
 
Fig. 22: Effect of lactogenic hormones [insulin (Ins), prolactin (PRL) and dexamethasone (DEX)] and growth factors 
(EGF and IGF-1) on gene expression of (A) urokinase plasminogen activator (u-PA) and (B) u-PA receptor (u-PAR) 
in BME-UV1 mammary epithelial cells after 24-h treatment. Treatment combinations were made using the highest 
concentration for each compound. All data are presented as means±SEM (n=4). Means without a common letter 
differ *P: <0·05. 
 
Treatment of cells with prolactin at the high concentration (1 μg/ml) caused a 
2-fold increase (P<0.05) in expression of u-PA. Dexamethasone alone or in 
combination with insulin or prolactin showed a tendency to decrease 
expression of u-PA but this decrease did not reach the designated level of 
significance (P>0.05). The effect of growth factors and lactogenic hormones 
on mRNA expression of PAI-1 and PAI-2 by bovine mammary epithelial cells 
was examined and the results are presented in Fig. 23. Dexamethasone alone 
A B 
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and when combined with insulin or prolactin increased by 2–3·5-fold 
expression of PAI-1 (Fig. 23A) and by 3–4-fold that of PAI-2 (Fig. 23B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.23: Effect of lactogenic hormones [insulin (Ins), prolactin (PRL) and dexamethasone (DEX)] and growth factors 
(EGF and IGF-1) on gene expression of (A) plasminogen activator inhibitor type 1 (PAI-1) and (B) plasminogen 
activator inhibitor type 2 (PAI-2) in BME-UV1 mammary epithelial cells after 24-h treatment. Treatment 
combinations were made using the highest concentration for each compound. All data are presented as means±SEM 
(n=4). Means without a common letter differ *P: <0.05. 
 
Treatment of cells with insulin had no effect (P>0.05) on expression of all 
four PA-related genes (u-PA, u-PAR, PAI-1 and PAI-2). However, treatment 
of cells with the high concentration of insulin (1 μg/ml) showed a trend for 
increasing expression of PAI-2, but was not significant (Fig. 23B). IGF-1 and 
EGF had no effect on PAI-1 and PAI-2 gene expression. The effect of 
growth factors and lactogenic hormones on total cell-associated, membrane-
bound and secreted u-PA activity was examined and the results are presented 
in Fig. 4. IGF-1 and EGF increased (P<0.001) total, membrane-bound and 
secreted u-PA activity on a per cell basis (Fig. 24); EGF increased total cell-
associated and membrane-bound activity more (P<0.01) than did IGF-1. 
Treatment of cells with prolactin at both concentrations (0.01 or 1 μg/ml) had 
no effect on all forms of u-PA activity. Insulin did not cause any significant 
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(P>0.05) change in any form of u-PA activity when compared with control 
values (Fig. 24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24: Effect of lactogenic hormones [insulin (Ins), prolactin (PRL) and dexamethasone (DEX)] and growth factors 
(EGF and IGF-1) on (A) total, (B) membrane-bound and (C) secreted plasminogen activator (PA) activity in BME-
UV1 mammary epithelial cells after 24-h treatment. Treatment combinations were made using the highest 
concentration for each compound. All data are presented as means±SEM (n=6). Means without a common letter 
differ *P: <0.05. 
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Consistent with the main effect concerning up-regulation of PAI-1 gene 
expression, dexamethasone when combined with insulin or prolactin 
decreased (P<0.05) all three forms of u-PA activity (Fig. 24) but surprisingly 
treatment with dexamethasone alone had no effect on u-PA activity. 
 
6.6 Discussion  
We investigated whether IGF-1 and EGF regulated the expression of genes 
implicated in activating (u-PA, u-PAR) or blocking (PAIs) the plasminogen 
activating cascade in the BME-UV1 non-invasive bovine mammary epithelial 
cell line. Our working hypothesis was that both growth factors enhance cell 
growth and up-regulate genes implicated in activating the system (u-PA, u-
PAR) and/or down-regulate genes implicated in blocking the activation of the 
system. We showed that both EGF and IGF-1 increased cell proliferation. 
With respect to gene expression, we found some subtle differences in the 
mode of action of these two growth factors. For example, EGF increased 
expression of u-PAR while IGF-1 up-regulated expression of both u-PA and 
u-PAR. Both growth factors affected neither the expression of PAI-1 nor the 
expression of PAI-2 by BME-UV1 cells. In a manner consistent with the 
expression data, both EGF and IGF-1 increased all forms of measured u-PA 
activity (total cell-associated, membrane-bound and secreted). These data 
taken together suggest that a relationship exists between cell proliferation and 
expression of the two genes implicated in the activation of the plasmin-
plasminogen system (u-PA, u-PAR). Our data suggest that EGF was a more 
effective mitogen than IGF-1. Furthermore, EGF increased the amount of u-
PA present in cell membranes more than that caused by IGF-1 presumably 
because EGF induced more u-PAR expression than IGF-1. These data are 
consistent with those of others (Alfano et al., 2005) who indicated that what 
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truly matters is the physical binding of u-PA to u-PAR, in addition to 
increased expression of u-PAR. In fact, Jo et al. (2007) proposed that both 
conditions are necessary for increased cell proliferation. Previous studies have 
provided conflicting results concerning whether activation of u-PA gene or 
activity is implicated in the mechanism through which IGF-1 affects cell 
proliferation. The present data suggesting that IGF-1 upregulated u-PA and u-
PAR without affecting any of the PAIs agree with those of Politis et al. (1995) 
who similarly reported up-regulation of u-PA together with elevated u-PA 
activity on a per cell basis in response to IGF-1. Similar results suggesting that 
IGF-1 is acting through induction of the u-PA/u-PAR system were provided 
by Dunn et al. (2000; 2001) using the highly invasive MDA-MB-231 breast 
cancer cell line. However, against this notion, Cheli et al. (2003) showed that 
retinoids inhibit insulin/IGF-1 mediated BMEUV cell proliferation but have 
no effect on u-PA mRNA levels and activity. Future u-PA/u-PAR gene 
silencing experiments will solve the discrepancy between these studies. With 
respect to the lactogenic hormones, we observed that dexamethasone alone 
and when combined with insulin or prolactin up-regulated expression of PAI-
1 and PAI-2 by BME-UV1 cells. The combination of dexamethasone and 
prolactin was more effective than dexamethasone alone or the combination of 
dexamethasone and insulin indicating a synergistic effect of dexamethasone 
and prolactin in upregulating PAI-1 but not PAI-2 synthesis. On the other 
hand, dexamethasone alone had no effect on u-PA expression but when used 
in combination with prolactin down-regulated the prolactin-induced increase 
in u-PA synthetic ability of the BME-UV1 cells. With respect to u-PA activity, 
dexamethasone alone had no effect but when combined with insulin or 
prolactin reduced all forms of measured u-PA activity (total cell-associated, 
membrane-bound and secreted). Thus, the prominent effect of 
dexamethasone in the BME-UV cells is its ability to down-regulate the 
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plasminogen activating cascade. None of the lactogenic hormones when used 
alone or combined had any effect on cell proliferation. This finding taken 
together with the expression data leads to two conclusions. First, the 
induction of PAI-1 and PAI-2 synthesis caused by dexamethasone and the 
overall down-regulation of the plasminogen activating cascade at the 
molecular and the protein levels are not related to cell growth. Second, the 
ability of prolactin to induce u-PA expression without an effect on u-PA 
activity suggests that changes in the u-PA system at the protein level together 
with physical binding of u-PA to u-PAR might be necessary for induction of 
cell growth. Our findings suggest that all modulators of mammary function 
studied regulate both plasminogen activator inhibitors (PAI-1 and PAI-2) in a 
similar manner, thus creating an apparently functionally redundant mechanism 
for inhibition of the system in bovine mammary epithelial cells. Both PAIs 
share a similar manner of action in blocking the PAs. Therefore, one of them 
could easily block the system, thus, making the second one redundant. The 
functional role of PAIs may no longer be simply to inhibit over-expressed 
PAs but they may serve some additional role in regulating mammary cell 
functions. Results from various mammary cell systems suggest that 
glucocorticoids exercise mainly an anti-proliferative effect on breast cancer 
cells (Lipka et al., 2004; Rubis et al., 2004). Furthermore, glucocorticoids 
suppress u-PA gene expression and activity (Henderson and Kefford, 1993; 
Politis et al., 1995b; Sasaki et al., 1999). Busso et al. (1987) reported that the 
glucocorticoid-induced inhibition of the plasminogen activating cascade was 
related to both a decrease in the synthesis of u-PA and a concomitant increase 
in the production of PAI-1 in the highly invasive MDAMB- 231 mammary 
carcinoma cell line. We showed that dexamethasone in BME-UV cells down-
regulated the plasminogen activating cascade at the molecular level by causing 
an increase in expression of both PAIs and by inhibiting the prolactin-induced 
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increase in expression of u-PA. Our data concerning the effect of prolactin 
and the lack of an insulin effect on expression of u-PA related genes and cell 
proliferation deserve some comments. With respect to prolactin, Politis et al. 
(1995) showed that prolactin had no effect on proliferation of MAC-T bovine 
mammary epithelial cells. In contrast, others have shown that prolactin 
enhanced proliferation of bovine mammary epithelial cells (Olazabal et al. 
2000) and that of the invasive MCF7 cells (Doll et al., 2007). Our data indicate 
that prolactin up-regulated expression of u-PA but had no effect on all forms 
of u-PA activity by BME-UV1 cells. Furthermore, as expected, prolactin had 
no effect on proliferation of BME-UV1 cells. These data taken together 
indicate that the induction of the u-PA gene alone does not support mammary 
epithelial cell proliferation but binding of u-PA to u-PAR might be necessary 
to prime mammary epithelial cells for enhanced proliferation. With respect to 
the lack of the insulin effect on u-PA expression, it was very surprising to us 
that insulin did not act in a similar manner to IGF-1. This is because the 
concentration of insulin used should have activated the IGF-1 receptor. The 
similarity of the effectiveness between insulin and IGF-1 in increasing both 
gene expression and activity of u-PA was demonstrated in the MAC-T cell 
line by Politis et al. (1995), which was derived in a similar manner to the 
BME-UV1 cell line. This discrepancy between the earlier and the present 
study cannot be explained, but we believe that the lack of the effect is not an 
artifact or a problem related to biological activity of the insulin used because 
the combination of insulin and dexamethasone was more effective in reducing 
all forms of PA activity than dexamethasone alone. In conclusion, IGF-1 and 
EGF increased cell proliferation and in parallel caused induction of the u-
PA/u-PAR system using the non-invasive bovine mammary epithelial BME-
UV1 cells as a model system. On the other hand, the prominent effect of 
dexamethasone was to induce PAI-1 and PAI-2 expression and overall to 
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down-regulate the plasminogen activating cascade at the molecular and 
protein levels. Alterations in the expression of PA-related genes and those 
observed at the protein level following treatment of BME-UV1 cells with 
dexamethasone or prolactin (induction of u-PA) are not related to bovine 
mammary epithelial cell growth. Further studies using various techniques of 
gene silencing will provide the ultimate answer as to whether u- PA and u-
PAR play a role in bovine mammary epithelial cell proliferation. 
 
2nd study 
 
6.7 Materials and methods  
6.7.1 Cell line and cell culture 
The origin of the BME-UV1 established bovine mammary epithelial cell line 
has been described previously (Zavizion et al., 1996b). Cells were routinely 
cultivated in plastic Petri dishes (Corning Glass, Corning, NY, USA) in 
complete medium, which was a mixture of 50% DME-F12, 30% RPMI-1640 
and 20% NCTC- 135 supplemented with 10% foetal bovine serum (FBS) 
(BioWhittaker, Cambrex, Belgium), 0.1% lactose, 0.1% lactalbumin 
hydrolysate, 1.2 mM glutathione, 1.0 µg/ml insulin, 5.0 µg/ml transferrin, 1.0 
µg/ml hydrocortisone, 0.5 µg/ml progesterone, 10.0 µg/ml L-ascorbic acid 
and antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin). All 
medium supplements were obtained from Sigma– Aldrich. Cells were 
maintained at 37°C in an incubator in a humidified atmosphere containing 5% 
CO2.  
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6.7.2 Cell viability assay 
Cell viability after incubation with LPS was determined by measuring the 
production of the chromophore formazan from 3-(4,5- dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide (MTT, Sigma– Aldrich), as previously 
described (Baldi et al., 2004). Formazan is produced in viable cells by the 
mitochondrial enzyme, succinate dehydrogenase. Briefly, BME-UV1 cells 
were exposed to increasing concentrations of E. coli LPS O111:B4 (0.1, 1.0 
and 10 µg/ml) (Sigma–Aldrich) in complete medium for 3, 6 and 12 h of 
incubation time. The concentrations were selected from a larger range of 
concentrations that were previously tested to correspond to subtoxic levels of 
LPS as described by Pecorini et al. (2010). Cells incubated with complete 
medium alone, representing 100% viability, were included as negative 
controls. At least three replicates were performed in each experiment, and 
each experiment was performed at least twice. The percentage of cell viability 
was calculated as follows:  
percentage viability = (mean optical density in the presence of LPS/mean 
optical density of negative control) x 100. 
 
6.7.3 Effect of LPS treatment on total BME-UV1 cell-associated u-PA 
To determine the effect of LPS on u-PA activity, total cell-associated u-PA 
activity was evaluated using a colorimetric assay (Politis et al., 1995a; Cheli et 
al., 2003). Briefly, cells were seeded in a 24-well tissue culture plate (0.5 x 106 
cells/ml) in complete culture medium containing 10% FBS. After 24 h, media 
were removed, cells were washed three times with HBSS and test medium was 
added. Test medium consisted of complete culture medium alone (control) or 
complete medium containing various concentrations (0.1, 1.0 and 10 µg/ml) 
of LPS. After incubation for 3, 6 and 12 h, cell monolayers were washed three 
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times with HBSS and treated with a mildly acidic solution (50 mM glycine–
HCl buffer and 0.1 M NaCl, pH 3.0) for 3 min to liberate membrane-bound 
u-PA. After adding the neutralizing solution (0.5 M Hepes buffer and 0.1 mM 
NaCl, pH 7.5), the fraction corresponding to membrane bound u-PA was 
collected and stored at -80°C for further analysis. Cells were then trypsinised 
by incubation at 37°C with 0.05% Trypsin– EDTA for approximately 5 min 
and counted in a haemocytometer. Finally, cells were lysed using lysis solution 
(1% Triton X-100, 20 mM Hepes buffer, and 10% glycerol, pH 7.5), and the 
lysates were cleared using centrifugation at 12,700g at 4°C for 30 min. The 
cleared lysates, containing intracellular u-PA, were stored at -80°C. At least 
three replicates were evaluated per treatment, and the experiment was 
performed at least twice. Total cell-associated (intracellular plus membrane 
bound) u-PA activity was measured using a colorimetric assay (Politis et al., 
1995a). This system utilises the enzymatically active u-PA present in the 
medium to convert exogenously supplied plasminogen to active plasmin. 
Plasmin then attacks the chromogenic substrate Val-Leu-Lys-p-nitroanilide 
(Sigma–Aldrich), thus liberating the free chromophore p-nitroanilide. In this 
system, changes in colour are directly related to plasmin amounts and, 
consequently, indirectly related to u-PA activity. Assays were performed in 
250 µl of 100 mM Tris buffer (pH 8.0) containing plasminogen (50 pg/ ml; 
Sigma–Aldrich), chromogenic substrate (6 mM) and 5 µl of medium from 
LPS-treated and non-treated cells. A sample without plasminogen served as a 
control. The reaction mixture was incubated for 3 h, and the absorbance was 
determined at 405 nm every 30 min using a Biorad 680 microplate reader 
(Biorad). The rate of p-nitroanilide formation was calculated from the linear 
part of the curve of absorbance versus time. Previous studies have 
demonstrated that u-PA activity is linear for up to 3 h of incubation (Politis, 
1996). 
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6.7.4 Determination of free u-PA-binding sites on the cell membrane 
It has been previously shown that the u-PA-binding sites on the cell 
membrane may be fully saturated (Politis et al., 2004). The u- PA-binding sites 
that are unoccupied can be fully saturated by the addition of purified u-PA. 
Therefore, the difference in membrane bound u-PA before and after this 
incubation correlates to the presence of free u-PA-binding sites on the cellular 
surface. Cells were seeded in a 24-well tissue culture plate in complete culture 
medium containing 10% FBS. After 24 h, media were removed, cells were 
washed three times with HBSS and test medium was added. Test medium 
consisted of complete culture medium either without (control) or with various 
concentrations (0.1, 1.0 and 10 µg/ml) of LPS. After 3, 6 and 12 h, media 
were removed, and cells were washed four times with HBSS. Then, cells were 
incubated in HBSS containing purified u-PA (10 units/ml; Sigma–Aldrich) to 
fully saturate all u-PA-binding sites on the cell membrane (Politis et al., 2002). 
After incubation for another 30 min at 37 °C, cells were washed three times 
with HBSS and treated with a mildly acidic solution to liberate u-PA from the 
cell surface, as mentioned previously. Membrane-bound u-PA activity was 
determined using the colorimetric assay described above. 
 
6.7.5 Effect of LPS exposure on u-PA and u-PAR mRNA expression  
6.7.5.1 LPS treatment 
BME-UV1 cells (0.2–0.4 x 106 cells/ml) were seeded in 60-mm Petri dishes in 
complete medium containing 10% FBS. After 24 h, media were removed, cells 
were washed three times with HBSS and test medium consisting of complete 
medium containing 0.1, 1.0, or 10 µg/ml of LPS were added. After 3, 6, and 
12 h, cells were harvested using trypsinisation, and total RNA was extracted 
using TRI Reagent (Sigma–Aldrich) and stored at -80°C until further analysis. 
103 
 
 
6.7.5.2 u-PA and u-PAR mRNA expression 
The reverse transcription (RT) reaction was performed on 1 µg RNA using an 
iScript™ cDNA Synthesis Kit (Biorad) using cycling conditions suggested by 
the manufacturer’s protocol. Quantitative reactions were performed in 25 µl 
of SYBR® Green mix (Biorad) using 350 nM b-actin and u-PA primers and 
450 nM u-PAR primers. The sequences of the primers used in the quantitative 
reactions are indicated in Table 4. Each sample was tested in duplicate. To 
evaluate the qRT-PCR efficiency, dilution series were prepared by performing 
fourfold serial dilutions starting from the reference samples. The thermal 
profile used (95°C for 90 s and 50 cycles of 95°C for 15 s and 62°C for 60 s; 
for melting curve construction, 55°C for 60 s and 80 cycles starting at 55°C 
and increasing 0.5°C each 10 s) was the same for each target gene. The results 
obtained were compared using the delta–delta Cq method (Giulietti et al., 
2001) after normalisation of the sample using the b-actin gene as the reference 
gene. 
Target Gene Primer sequence (5’→3’) Product length 
β- actin Sense CCAAAGCCAACCGTGAGA 133 bp 
 Antisense CCAGAGTCCATGACAATGC  
u-PA Sense GGCCAGAAGGCTCTGAGGC 133 bp 
 Antisense GGCTGCCACCACACAAGTAGG  
u-PAR Sense GGGACAGGACCTCTGCAGG 117 bp 
 Antisense CGATAGCTCAGGGTCCTGTTG  
 
Table 4: Sequences of the primers used in the quantitative PCR reactions. 
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6.8 Statistical analysis  
Results are presented as the mean and SD. The effects of incubation time and 
various treatments were evaluated using a one-way analysis of variance using 
the GLM procedure of SAS (version 9.1, SAS Institute Inc., Cary, NC, USA). 
Mean comparisons were per performed using Duncan’s multiple range test, 
with P < 0.05 as the level of significance. 
 
6.9 Results  
6.9.1 LPS had no effects on cell viability 
Endotoxin had no significant effect on cell viability, confirming the results 
previously published by Pecorini et al. (2010). Moreover, when observed 
under the microscope, treated cells did not show visible morphological 
differences compared to control cells (data not shown). 
 
6.9.2 LPS modulated total BME-UV1 cell-associated u-PA activity 
LPS stimulated total cell-associated u-PA activity at 6 h of treatment in the 
presence of 1.0 and 10 µg/ml LPS (P < 0.05 and P = 0.07, respectively; Fig. 
25). When LPS was used, u-PA activity increased after 6 h of incubation, but 
at 12 h, u-PA activity decreased to control levels, showing a time-dependent 
effect (P < 0.01). u-PA activity in control cells did not show any significant 
variation up to 12 h of treatment.  
105 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25: Effect of LPS on total cell-associated u-PA activity in BME-UV1 mammary epithelial cells after 3, 6 and 12 
h of treatment. All data are presented as means and SD. 
 
Membrane-bound u-PA levels were also measured. The results indicated that 
in both treated and control BME-UV1 cells, u-PA binding sites on the cell 
membrane were fully saturated (data not shown). Therefore, no free u-PA-
binding sites were available at the cellular surface, indicating that once 
produced at the cellular level, u-PA is immediately bound to its receptor.  
 
6.9.3 LPS up-regulated u-PA and u-PAR mRNA expression 
To assess whether LPS could modulate u-PA mRNA levels, the relative 
quantification of u-PA mRNA was performed using qRT– PCR. The gene 
expression levels of u-PAR were also investigated. Complementary DNA was 
relatively quantified using the delta– delta Cq method after normalisation of 
the sample using b-actin as the reference gene. Results are presented in Fig. 
26. Both u-PA and u-PAR mRNA expression were up-regulated in BME-UV1 
cells after 3 h of incubation with LPS compared to control cells (P < 0.01; Fig. 
26). The LPS effect was not dose dependent, but it was time dependent. In 
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fact, the peak induction was observed 3 h after stimulation, after which u-PA 
and u-PAR levels returned to control levels, and no statistically significant 
regulatory activity was detected after 6 h of stimulation. 
 
 
 
Fig. 26: Effect of subtoxic doses of LPS on the gene expression of (A) urokinase plasminogen activator (u-PA) and 
(B) u-PA receptor (u-PAR) in BME-UV1 mammary epithelial cells after 3, 6 and 12 h of treatment. All data are 
presented as means and SD. 
 
6.10 Discussion  
The available evidence indicates that bovine mammary epithelial cells respond 
to bacterial LPS and other microbial products through the activation of 
signaling pathways necessary to mount defensive mechanisms against 
pathogens (Bruckmaier, 2005; Bannerman, 2009; Pecorini et al., 2010). The 
present study has shown that exposure to LPS induced an up-regulation of 
gene expression levels of u-PA and u-PAR in a bovine mammary epithelial 
cell line. u-PA enzymatic activity was also increased. Several studies have 
shown that the PA system plays a role in inflammatory responses during 
mastitis (Long et al., 2001; Politis et al., 2002; Zhao and Lacasse, 2008; 
Theodorou et al., 2010). To the best of the authors’ knowledge, this is the first 
study providing evidence that the plasminogen activator system is involved in 
cellular responses to LPS in bovine mammary epithelial cells in vitro. These 
results are consistent with previous reports that demonstrated the induction 
A B 
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of u-PA expression in response to pathogens (Cheng et al., 2009; Ohta et al., 
2000; Oikawa et al., 1993). Previous results by Zavizion et al. (1997) have 
shown that u-PA activity is increased in BME-UV1 cells after stimulation with 
Staphylococcus aureus, whereas our findings indicate that the PA system is 
enhanced in response to LPS challenge. Together, these data suggest that the 
PA system plays a key role in cellular responses to both Gram-positive and 
Gram-negative bacterial infections in the mammary gland. The increase in u-
PA activity is probably induced by an up-regulation of the expression of the 
genes within the PA system, because quantitative gene expression data 
demonstrated that both u-PA and u-PAR mRNA were overexpressed after 3 
h. The early response of u-PA and u-PAR gene expression suggests that the 
PA system may be activated in mammary epithelial cells during the initial 
phase of the inflammatory response. The role of u-PAR is to restrict u-PA 
proteolytic activity to the cell surface. BME-UV1 cells produce and secrete u-
PA, which binds to the u-PAR present on the cell surface (Politis, 1996). The 
results of this study represent evidence that u-PA-binding sites on the cell 
membrane of BME-UV1 cells are fully saturated because no difference in u-
PA activity before and after saturation with purified u-PA was observed. It is 
therefore plausible that the harmonised expression of both of these 
components of the PA system in BME-UV1 cells maximises cellular 
responses to invading pathogens. In this context, the activation of the u-PA 
system might not only favour the recruitment of neutrophils to the site of 
inflammation but also activate the release of pro-inflammatory mediators, thus 
enhancing the acute inflammatory reaction (Mondino and Blasi, 2004). In fact, 
the involvement of the u-PA/u-PAR system in the regulation of inflammation 
is not confined within the activation of the fibrinolysis system. There is 
growing evidence that both u-PA and u-PAR fulfill important roles during 
innate immunity reactions, such as the upregulation of LPS-induced 
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neutrophil activation, chemotaxis and reactive oxygen species (ROS) 
(Abraham et al., 2003; Boyle et al., 1987; Cao et al., 1995). The short lag 
between stimulation with LPS and the increase in u-PA/u-PAR mRNA 
expression (3 h) suggests that the u-PA system belongs to the network of 
molecules that are overexpressed during the first phases of the innate immune 
reaction against invading pathogens, with the aim to potentiate the clearance 
of bacteria by neutrophils. An additional finding of this study was that LPS 
stimulation was followed by a peak of u-PA activity after 6 h of LPS exposure, 
whereas gene expression was statistically significant after 3 h. The discrepancy 
between the u-PA protein peak (6 h) and the u- PA mRNA peak (3 h) can be 
explained by the timeframe necessary for the protein to be synthesised and 
post-translationally modified within the cells. Interestingly, u-PA enzymatic 
activity returned to baseline after 12 h of stimulation. A possible explanation 
of this finding suggests the involvement of PAIs during the latter part of the 
inflammatory response, thus limiting the plasminogen-activating cascade 
(Theodorou et al., 2010). It has been shown that the binding of PAI-1 
facilitates internalisation of the u-PA/u-PAR complex within the cell, 
therefore providing a strategy to modulate the proteolytic activity on the cell 
membrane (Politis, 1996). Zavizion et al. (1996a) reported the synthesis of 
PAI-1 by BME-UV1 cells, and recent studies performed in our laboratory 
showed that some modulators of mammary function regulated both PAI-1 
and PAI-2 in a similar manner (Theodorou et al., 2011). It is also noteworthy 
that there was a decrease in both u-PA and u-PAR mRNA expression after 6 
h of stimulation with LPS. Therefore, the reduction in u-PA activity is likely to 
be induced by a combination of down regulation of gene expression and 
protease inhibition by PAI. Future work will be necessary to investigate the 
functional significance of PAIs in the plasminogen cascade in mammary 
epithelial cells during inflammation. u-PA may serve multiple functions at the 
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cellular level under both physiological and pathological conditions, including 
cell proliferation and migration, tissue remodeling and inflammation 
(Mondino and Blasi, 2004). In the present study, BME-UV1 cells exposed to 
LPS showed increased u-PA expression and activity, which was independent 
from cell viability and cell appearance. This result indicates an effect of LPS 
without any impact on mammary epithelial cell proliferation. In conclusion, 
the present study revealed that E. coli LPS induced an increase in u-PA 
expression and activity in association with an increase in u-PAR mRNA levels. 
These novel findings support the biological significance of the PA system 
during pathological processes and strengthen the role of mammary epithelial 
cells in mounting an inflammatory response against invading pathogens. 
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7. Conclusion  
My PhD was focused on the evaluation of nutraceutical bioactive compounds 
using cell-based assay, particularly in view of the need to use alternatives to 
animal studies.  
Data described in the first section of my thesis showed the cellular inhibition, 
associated with the LDH release and DNA fragmentation, induced by in vitro 
OTA challenges in ear and embryo porcine fibroblasts cultures.  Both primary 
porcine fibroblast cultures offer new in vitro opportunities to study Ochratoxin 
A (OTA) cytotoxicity. Furthermore obtained results demonstrated that α-
tocopherol supplementation may counteract short-term OTA toxicity at 
different cellular levels, supporting its defensive role in the cell membrane.  
The results of the second part of my study showed that in BME-UV1 cells, 
exogenous bovine Lactoferrin (bLF) acts as a protective factor, confirming 
the defensive role of bLf probably related to its cationic nature, which allows 
the neutralization of LPS. In addition our data showed that the response to 
LPS treatments does not involve endogenous bLf mRNA expression, in 
BME-UV1 mammary cell line probably due to the lack of functional LPS-
responsive elements bacterial lipopolysaccharides (LPS). 
The third part, focalized on the cellular response of Plasmin-plasminogen 
system to both physiological and cytotoxic stimuli in bovine mammary 
epithelial BME-UV cells as a model system, showed that IGF-1 and EGF 
increased cell proliferation and in parallel caused induction of the u-PA/u-
PAR system. On the other hand, the prominent effect of dexamethasone was 
to induce PAI-1 and PAI-2 expression and overall to down-regulate the 
plasminogen activating cascade at the molecular and protein levels. Alterations 
in the expression of PA-related genes and those observed at the protein level 
following treatment of BME-UV1cells with dexamethasone or prolactin 
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(induction of u-PA) are not related to bovine mammary epithelial cell growth. 
Furthermore the present study revealed that E. coli LPS induced an increase in 
u-PA expression and activity in association with an increase in u-PAR mRNA 
levels. These novel findings support the biological significance of the PA 
system strengthening the role of mammary epithelial cells in mounting an 
inflammatory response against invading pathogens. Plasmin-plasminogen 
system has a key role during mammary gland development and pathological 
processes. 
 
In conclusion in order to use nutraceuticals in both human and animal 
nutrition, it is important to develop protocols and models to evaluate the 
bioaccessibility, bioavailability and functionality of the bioactive components. 
The approach to cell-based bioassays supports the new need for food/feed 
analysis in terms of bioactivity and functional properties.  
According to our results cell-based assays are a valuable tool for assessing 
fundamental regulatory mechanisms at a cellular level. Cell-based assays are a 
valuable tool for assessing fundamental regulatory mechanisms at a cellular 
level, such as the plasmin-plasminogen system. Cell-based assays allow both 
the functionality of nutraceutical and cellular response mechanisms to be 
evaluated reducing use animal models in the preliminary study phase. 
Obviously, data obtained in cell culture models must be interpreted carefully, 
since this system represents a simplification of the intricacies of the numerous 
reactions and interactions that occur in vivo. 
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